paclitaxel has been researched along with Peripheral Nervous System Diseases in 556 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (0.72) | 18.7374 |
| 1990's | 68 (12.23) | 18.2507 |
| 2000's | 126 (22.66) | 29.6817 |
| 2010's | 217 (39.03) | 24.3611 |
| 2020's | 141 (25.36) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, JY; Chen, CT; Chen, LH; Chen, YF; Chou, MC; Lai, YP; Lee, CJ; Lee, HW; Lee, JC; Shen, MR; Shia, KS; Song, JS; Wu, CH; Wu, HL; Yeh, KC; Yeh, TK | 1 |
| Ligtenberg, M; Steegers, M; van den Heuvel, S; van Haren, F; Vissers, K | 1 |
| Arikan, SM; Dogan, T; Kandemir, FM; Kaynar, O; Semis, HS | 1 |
| Araldi, D; Bonet, IJM; Green, PG; Levine, JD; Staurengo-Ferrari, L | 1 |
| DiSilvestro, PA; Filiaci, VL; Fowler, JM; Huang, HQ; Matei, D; Matulonis, UA; Miller, DS; Moxley, KM; Mutch, DG; Nakayama, JM; Powell, MA; Randall, M; Richards, WE; Spirtos, NM; Tewari, KS; Wenzel, LB | 1 |
| Domoto, R; Iemura, M; Kamaguchi, R; Kawabata, A; Nishibori, M; Sekiguchi, F; Tsubota, M; Wang, D; Yamanishi, H | 1 |
| Avizonis, D; Bergholz, JS; Chen, CY; de Sá Tavares Russo, M; DiAntonio, A; Hsueh, YP; Jiang, T; Ko, KW; Li, Y; Milbrandt, J; Pazyra-Murphy, MF; Segal, RA; Tang, S; Zhao, JJ; Zhu, J | 1 |
| Beesley, VL; Campbell, R; DeFazio, A; Friedlander, ML; Grant, P; King, MT; Nagle, CM; Obermair, A; Ross, TL; Webb, PM | 1 |
| Asano, H; Hiramoto, S; Kawabata, A; Miyamoto, T; Takegami, M | 1 |
| Bales, CL; Cantor, EL; Cunningham, GM; Fehrenbacher, JC; Gardner, L; Jiang, G; Liu, Y; Philips, S; Schneider, BP; Shen, F; Tan, Z; Wan, J; Wu, X | 1 |
| Adamek, P; Bhattacharyya, A; Heles, M; Palecek, J; Pontearso, M; Slepicka, J | 1 |
| Alvisi, MF; Benedetti Panici, P; Biagioli, E; Bologna, A; Carlucci, L; Colombo, N; DeCensi, A; Fossati, R; Lapresa, M; Lissoni, AA; Mancari, R; Nicoletto, MO; Palaia, I; Poli, D; Rulli, E; Tasca, G; Tettamanzi, F; Tognon, G; Tomao, F; Torri, V | 1 |
| Jue, MY; Nisar, T; Shah, D; Stiles, A | 1 |
| Chen, L; Derstine, BA; Griggs, JJ; Hayes, DF; Henry, NL; Hertz, DL; Pai, MP; Su, GL; Wang, SC | 1 |
| de la Torre-Martínez, R; Fernández-Carvajal, A; Ferrer-Montiel, A; Villalba-Riquelme, E | 1 |
| Bangemann, N; Blohmer, JU; Boehmerle, W; Dordevic, AD; Endres, M; Göpfert, JC; Hew, L; Huehnchen, P; Kern, J; Körtvelyessy, P; Maierhof, SK; Nolte, L; Ruprecht, K; Schinke, C; Sehouli, J; Somps, CJ | 1 |
| Achariyapota, V; Chitkumarn, P; Rahong, T | 1 |
| Feng, S; Mao, M; Wang, J; Wang, X; Zhang, S; Zhou, F | 1 |
| Asama, H; Hashimoto, M; Hikichi, T; Irie, H; Kato, T; Kobashi, R; Konno, N; Nakamura, J; Ohira, H; Okubo, Y; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T; Takasumi, M | 1 |
| Cubillos-Ruiz, JR; Dougherty, PM; Fonseca, MM; Morgan, JW; Pennypacker, SD; Romero-Sandoval, EA; Strowd, RE | 1 |
| Alberti, P; Alemany, M; Argyriou, AA; Bruna, J; Cavaletti, G; Dinoto, A; Ferrari, S; Kalofonos, HP; Kalofonou, F; Karteri, S; Mariotto, S; Stradella, A; Velasco, R; Velissaris, D | 1 |
| Goode, DJ; Mecum, NE; Whitaker, EE | 1 |
| Holotiuk, IS; Holotiuk, SI; Holotiuk, VV; Kryzhanivska, AY; Maliborska, SV | 2 |
| Aprile, G; Catalano, M; Conca, R; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Elshafiey, RA; Elzawawy, S; Ghoneim, A; Mostafa, TM; Werida, RH | 1 |
| Allegretti, M; Amendola, PG; Aramini, A; Beccari, A; Benedetti, E; Brandolini, L; Bugatti, A; Caruso, A; Castelli, V; Cimini, A; Cocchiaro, P; Cristiano, C; Cunha, TM; d'Angelo, M; D'Egidio, F; Giorgio, C; Iaconis, D; Manelfi, C; Novelli, R; Quadros, AU; Ruocco, A; Russo, R; Sirico, A; Talarico, C | 1 |
| Aissouni, Y; Balayssac, D; Busserolles, J; Chapuy, E; Collin, A; Condé, S; Dalbos, C; Dumontet, C; Martin, PY; Mattévi, C; Richard, D; Selvy, M | 1 |
| Mellerick, A; Nicolae, R; Siderov, J; Uccellini, A; Wong, V; Yeo, B | 1 |
| Chen, CS; Henry, NL; Hertz, DL; Smith, EML; Stringer, KA | 1 |
| Chen, Y; Gan, P; Lu, R; Wang, Y | 1 |
| Ishikawa, T; Kanbayashi, Y; Katoh, N; Sakaguchi, K; Tabuchi, Y; Taguchi, T; Takagi, R; Takayama, K; Yokota, I | 1 |
| Antonio-Aguirre, B; Armenta-Quiroga, AS; Catalán, R; Espinosa-Fernandez, JR; Estrada-Mena, FJ; Freyria, A; Guijosa, A; Ortega-Treviño, MF; Perez-Ortiz, AC; Villarreal-Garza, C | 1 |
| Ahuja, A; Khurana, A; Rani, S; Sachdeva, S; Sardana, K; Savitha, B | 1 |
| Dalton, SO; Dominiak, HSH; Hasselsteen, SD; Herrstedt, J; Labudovic, D; Nielsen, SW; Reiter, L | 1 |
| Chen, CY; Pai, HC; Yang, TT | 1 |
| Ajisawa, K; Fujii, H; Hayashi, H; Iihara, H; Kobayashi, R; Makiyama, A; Ohata, K; Okumura, N; Sadaka, S; Suzuki, A; Tanaka, Y; Yasufuku, I | 1 |
| Argyriou, AA; Bruna, J; Ferrari, S; Hernández, J; Marco, C; Mariotto, S; Pernas, S; Stradella, A; Velasco, R | 1 |
| Burgess, BL; Cho, E; Honigberg, L | 1 |
| Aruga, T; Koibuchi, Y; Kosaka, Y; Masuda, N; Osaki, A; Saeki, T; Suzuki, R; Takano, T; Watanabe, J; Yamashita, T | 1 |
| Shin, GJ | 1 |
| Cao, M; Li, H; Lv, Z; Ma, F; Mo, H; Pan, B; Song, G; Sun, X; Teng, Y; Xu, B; Yan, X; Zhai, J; Zhao, F; Zhao, J | 1 |
| Hamada-Nishimoto, M; Kang, Y; Katayama, T; Tsuyuki, S | 1 |
| Friedlander, ML; Goldstein, D; Guennewig, B; Harrison, M; Hooshmand, K; Kwok, JB; Lees, JG; Lewis, CR; Li, T; Moalem-Taylor, G; Park, SB; Timmins, HC | 1 |
| Bergmann, TK; Herskind, K; Iversen, DB; Madsen, JS; Mortensen, C; Olsen, DA; Pottegård, A; Simonsen, E; Stage, TB; Steffensen, KD | 1 |
| Itoh, K; Schiller, PW; Shimoyama, M; Toyama, S | 1 |
| Dehghani, F; Elfarnawany, A | 1 |
| Cao, M; Li, H; Lv, Z; Ma, F; Mo, H; Pan, B; Sun, X; Xu, B; Zhai, J; Zhao, F; Zhao, J | 1 |
| Chu, T; Han, B; Lou, Y; Lu, J; Wang, H; Zhang, W; Zhang, X; Zhang, Y; Zhong, H; Zhong, R | 1 |
| Alberti, P; Ballarini, E; Bossi, M; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Crippa, L; Marmiroli, P; Monza, L; Pozzi, E; Rodriguez-Menendez, V | 1 |
| Huang, Y; Li, W; Ouyang, X; Shen, X; Wang, J; Xu, R; Zhao, X; Zhu, D | 1 |
| Borges Paes Lemes, J; Delay, L; Dos Santos Aggum Capettini, L; Dougherty, PM; Gonçalves Dos Santos, G; Gonzalez, L; Gregus, AM; Lu, JW; Miller, YI; Navia-Pelaez, JM; Yaksh, TL | 1 |
| Aghabozorgi, R; Babaee, M; Hashemi, M; Hesam, M; Rayegani, SM; Zahed, G | 1 |
| Arunmozhimaran, E; Batra, A; Chandran, DS; Gogia, A; Khurana, S; Kumar, A; Malik, PS; Pandey, P; Pushpam, D; Singh, MB | 1 |
| Ba, X; Hao, Y; Ho, IHT; Jiang, C; Li, N; Li, R; Liu, X; Sun, W; Wang, J; Wu, S; Xiao, L; Xiong, D | 1 |
| Abdel Hafez, SMN; El-Daly, M; Hammad, ASA; Ibrahim, ARN; Khalifa, MMA; Sayed-Ahmed, MM | 1 |
| Bao, T; Dreyfus, N; Galantino, M; Kot, KL; Lessing, A; Li, S; Piulson, L; Zhi, WI | 1 |
| Chou, PR; Hsieh, MC; Huang, SH; Lu, IC; Tai, MH; Wang, SH; Wu, SH | 1 |
| Itagaki, T; Kimura, Y; Shigematsu, H; Yasui, D | 1 |
| Chang, HS; Chang, YC; Chen, YF; Chiu, CC; Lin, HC; Lo, YC | 1 |
| Cathcart-Rake, EJ; Childs, DS; Kochan, DC; Novotny, PJ; Orme, JJ; Ruddy, KJ; Tevaarwerk, AJ | 1 |
| Cantor, E; Dang, C; Gardner, L; Jiang, G; Ly, RC; Miller, KD; Northfelt, D; Osei, W; Philips, S; Schneider, BP; Shen, F; Skaar, T; Sledge, GW; Wu, X; Xue, G | 1 |
| Albin, B; Tiwari, AP; Tristan, LJC; Yang, IH | 1 |
| Hucho, T; Imhof, T; Isensee, J; Klein, I; Koch, M; Lehmann, HC; Müller, C; Wassermann, MK; Wiesen, MHJ | 1 |
| Eltantawy, A; Haroun, EA; Mansour, NO; Shams, MEE | 1 |
| Arizono, K; Hiroka, Y; Ichikawa, N; Miyasaka, K; Mizukami, M; Niwa, K; Sakaguchi, Y | 1 |
| Ahmad, A; Boitano, S; DeFea, KA; Dussor, G; Kume, M; Price, TJ; Vagner, J | 1 |
| Baek, JM; Jeon, YW; Kang, YJ; Kim, D; Kim, YS; Oh, SJ; Rhu, J; Yang, YJ; Yi, JP; Yoon, CI | 1 |
| Bhangale, T; Chandler, GS; Crow, M; Hackos, DH; Jung, M; Kaminker, JS; Khan, Z; Maiya, V; McCarthy, MI; Mohindra, R | 1 |
| Chen, J; Chen, Y; Liu, X; Xing, H; Yan, M; You, M; Zhang, J; Zhu, J | 1 |
| Lei, HY; Lian, WY; Lu, ZP; Xu, SY; Zou, JQ | 1 |
| Chen, J; Chen, Y; Liu, X; Xing, H; Yan, M; You, M; Zhang, J; Zhang, S; Zhu, J | 1 |
| Barton, DL; Brown-Glaberman, UA; Dayao, ZR; Lafky, JM; Loprinzi, CL; Pankratz, VS; Tawfik, B | 1 |
| Anastasio, MK; Erkanli, A; Havrilesky, LJ; Hayes, T; Moss, HA; Scott, A; Shah, S; Unnithan, S | 1 |
| Adhikari, P; Albin, B; Qubbaj, K; Tiwari, AP; Yang, IH | 1 |
| Albain, KS; Ambrosone, CB; Barlow, WE; Budd, GT; Chen, CS; Damaj, MI; Godwin, AK; Henry, NL; Hertz, DL; Hortobagyi, GN; McKiver, B; Pusztai, L; Stringer, KA; Thompson, A; Zirpoli, G | 1 |
| Ihara, Y; Imai, T; Kawai, R; Kimura, T; Otani, M; Sawa, K; Shintani, A; Takatori, S | 1 |
| Abrams, G; Chesney, M; Conley, YP; Kober, KM; Levine, JD; Melisko, M; Miaskowski, C; Paul, SM; Schumacher, M; Topp, K | 1 |
| Chan, YN; Chen, CY; Jheng, YW; Lin, MW; Wang, PJ; Wang, YJ | 1 |
| Resham, K; Sharma, SS | 1 |
| Beutler, A; Dockter, T; Grosse-Perdekamp, MT; Lacouture, ME; Le-Rademacher, J; Loprinzi, CL; Onitilo, AA; Ruddy, KJ; Tan, AD; Vander Woude, AC; Wilkinson, M | 1 |
| Bland, KA; Bovard, J; Campbell, KL; Davis, MK; Gelmon, KA; Kirkham, AA; McKenzie, DC; Shenkier, T; Zucker, D | 1 |
| Doi, A; Inoue, M; Kanzaki, H; Katata, Y; Kuramochi, H; Nagasaka, T; Nasu, J; Okita, H; Satake, H; Shindo, Y; Tanioka, H; Uno, F; Yamaguchi, Y; Yamashita, H | 1 |
| Hanai, A | 1 |
| Caillaud, M; Damaj, MI; Fehrenbacher, JC; Rieger, S; Segal, RA; Staff, NP | 1 |
| Iida, Y; Odajima, S; Okamoto, A; Saito, M; Tabata, J; Ueda, K; Yamada, K; Yanaihara, N; Yokomizo, R | 1 |
| Du, J; Fang, J; Li, X; Li, Y; Liang, Y; Liu, B; Shao, X; Wang, J; Yin, C; Zheng, X | 1 |
| Barry, WT; Gobburu, JV; Gray, E; Hudis, C; Lad, TE; Lyss, AP; Mehrotra, S; Moreno-Aspitia, A; Overmoyer, B; Ratain, MJ; Rugo, HS; Sharma, MR; Toppmeyer, DL; Velasco, M; Winer, EP; Wu, K | 1 |
| Ang, E; Ang, S; Bandla, A; Chan, A; Chan, G; Hairom, Z; Huang, Y; Kumarakulasinghe, NB; Lee, SC; Lee, YM; Lim, JSJ; Magarajah, G; Ngoi, N; Sundar, R; Tan, S; Thakor, N; Wilder-Smith, E; Wong, A | 1 |
| Beutler, AS; Burness, ML; Gersch, CL; Griggs, JJ; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Marcath, LA; Rae, JM; Smith, EML; Van Poznak, C; Vangipuram, K | 1 |
| Boku, N; Hashimoto, H; Hirano, H; Honma, Y; Iwasa, S; Kato, K; Makino, Y; Okita, N; Otsuka, R; Sekiguchi, M; Shoji, H; Takashima, A; Yamaguchi, M; Yanai, T | 1 |
| Barker, MR; Etz, RS; Farris, KB; Gonzalez, M; Henry, NL; Hertz, DL; Krumbach, EK; Quinn, CS; Reed, HL; Salgado, TM; Syverson, JG; Vangipuram, K; Wenceslao, I | 1 |
| Hiramatsu, M; Ishikawa, T; Kanbayashi, Y; Kanehisa, F; Katoh, N; Nakatsukasa, K; Ouchi, Y; Sakaguchi, K; Tabuchi, Y; Taguchi, T; Takagi, R; Yokota, I | 1 |
| Hirata, T; Nishina, M; Ozaki, S; Shigematsu, H; Yasui, D | 1 |
| Chang, LY; Chang, MS; Chen, LH; Chen, YF; Hsu, YH; Lin, CK; Lin, PC; Shen, MR; Wang, HH; Yeh, YM | 1 |
| Jin, L; Yang, W; Zhang, Y | 1 |
| Burness, ML; Fang, F; Griggs, JJ; Hayes, DF; Henry, NL; Hertz, DL; Jennaro, TS; Kidwell, KM; Smith, EML; Van Poznak, C; Vangipuram, K | 1 |
| Beutler, AS; Farris, KB; Henry, NL; Hertz, DL; Le-Rademacher, J; Liu, J; Lopez, CL; Loprinzi, CL; Quinn, CS; Reed, HL; Salgado, TM; Smith, EML; Syverson, JG; Vangipuram, K | 1 |
| Farquhar-Smith, P; Gordon-Williams, R | 1 |
| Dille, S; Hansen, R; Harde, J; Marschner, N; Nusch, A; Potthoff, K; Söling, U; Stötzer, O | 1 |
| Hammer, HS; Khalaf, S; Kroetz, DL; Mortensen, C; Nielsen, F; Poetz, O; Rodriguez-Antona, C; Stage, TB; Steffensen, V; Svenningsen, ÅF; Xiong, C | 1 |
| Fujiwara, Y; Hasegawa, J; Hashimoto, K; Ikeda, K; Kawabata, H; Nishizawa, D; Ozaki, Y; Shimizu, C; Shimomura, A; Shiraishi, S; Takano, T; Tamura, K; Tamura, N; Tanabe, Y; Yonemori, K; Yunokawa, M | 1 |
| Alberti, P; Blennow, K; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Fumagalli, G; Marmiroli, P; Meregalli, C; Monza, L; Pozzi, E; Zetterberg, H | 1 |
| Huang, LD; Wang, GJ; Xiao, Y; Zhang, X | 1 |
| Blum, C; Gibson-Corley, KN; Hamity, MV; Hammond, DL; White, SR | 1 |
| Albany, C; Costello, BA; Dockter, T; Einhorn, L; Lafky, JM; Le-Rademacher, J; Loprinzi, CL; Ma, C; Pachman, D; Smith, E; Staff, N; Wagner-Johnston, N; Wolfe, E | 1 |
| Bhattacharya, MRC | 1 |
| Alkhlaif, Y; Contreras, KM; Damaj, MI; Meade, JA; Obeng, S; Selley, DE; Sim-Selley, LJ; Toma, W | 1 |
| Chua, KC; Friedman, PN; Ho, C; Jiang, C; Kroetz, DL; Kubo, M; Lai, D; McLeod, HL; Mulkey, F; Mushiroda, T; Owzar, K; Rashkin, SR; Ratain, MJ; Rugo, HS; Schneider, BP; Shulman, LN; Witte, JS; Xiong, C | 1 |
| Aboelhassan, R; El Wakeel, LM; Khalefa, HG; Shawki, MA | 1 |
| Abercrombie, TJ; Corrales, G; Dougherty, PM; Johansson, CA; Li, Y; Marri, T; North, RY; Rao, G; Rhines, LD; Rhodes, HR; Tatsui, CE; Uhelski, ML | 1 |
| Cheung, CW; Gu, P; Iadarola, M; Saligan, L; Ti, LK; Wang, XM; Wong, SSC | 1 |
| Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY | 1 |
| Rad, A; Sadeghi, E; Taheri, A; Varshosaz, J | 1 |
| Chung, CG; Hong, YB; Jeong, DJ; Kim, C; Kim, DH; Kim, JK; Kim, YY; Koh, H; Lee, SB; Shin, DJ; Um, JH; Yoon, JH; Yun, J | 1 |
| Braga, AV; Cassali, GD; Coelho, MM; de Barros, ALB; Fernandes, RS; Leite, EA; Machado, RR; Oda, CMR; Reis, DC; Silva, JO | 1 |
| Berrellez, D; Chhugani, N; Gupta, RS; Luna Lopez, C; Maldonado, A; Shah, SB | 1 |
| Fischbach, C; Kalish, M; Pabst, L; Petit, T; Pflumio, C; Pivot, X; Velten, M | 1 |
| Altman-Merino, A; Canato Ferracini, A; Chan, D; Chua, KC; Fattahi, F; Kim, J; Kroetz, DL; Priotti, J; Saraf, K; Stage, TB; Xiong, C | 1 |
| Baeyens, JM; Bravo-Caparrós, I; Cabeza, L; Cañizares, FJ; Fernández-Segura, E; Jiménez-López, J; Melguizo, C; Nieto, FR; Ortiz, R; Perazzoli, G; Prados, J | 1 |
| Brady, BL; Chebili, CL; Cooper, C; Dokubo, I; Fox, KM; Lucci, M; Varker, H; Wilson, K; Wojtynek, J | 1 |
| Hertz, DL | 1 |
| Bolon, B; Moore, MJ; Pollard, KJ | 1 |
| Alkhlaif, Y; Caillaud, M; Contreras, KM; Damaj, MI; Gewirtz, DA; Jackson, AB; Patel, NH; Poklis, J; Roberts, JL; Toma, W; Tran, TH; White, A; Wood, M | 1 |
| Alberti, P; Ballarini, E; Canta, A; Cavaletti, G; Chiorazzi, A; Fumagalli, G; Guarnieri, C; Marmiroli, P; Meregalli, C; Monza, L; Oggioni, N; Pozzi, E; Rodriguez-Menendez, V; Scali, C | 1 |
| Boyle, F; Friedlander, M; Goldstein, D; Harrison, M; Kiernan, MC; Li, T; Park, SB; Timmins, HC; Trinh, T | 1 |
| Au, K; Battaglini, E; Geelan-Small, P; Goldstein, D; Grimison, P; Henderson, RD; Ke, H; Li, T; Marker, J; Mizrahi, D; Park, SB; Timmins, HC; Trinh, T; Wall, B; Wyld, D | 1 |
| Chen, R; Du, J; Fang, J; He, X; Jiang, Y; Li, Y; Liang, Y; Liu, B; Nie, H; Wang, J; Yin, C; Zeng, D | 1 |
| Hiraiwa, R; Iguma, Y; Imai, S; Iwamitsu, Y; Kawaguchi-Sakita, N; Kotake, T; Koyanagi, M; Matsubara, K; Matsumoto, M; Nagayasu, K; Nakagawa, S; Nakagawa, T; Ntogwa, M; Ogihara, T; Omura, T; Saigo, M; Yonezawa, A | 1 |
| Bagdas, D; Caillaud, M; Donvito, G; Gewirtz, DA; Imad Damaj, M; Jackson, A; Lichtman, A; Makriyannis, A; Malamas, MS; Patel, NH; Roberts, J; Toma, W; Tran, TH | 1 |
| Albert, V; Bobylev, I; Joshi, AR; Klein, I; Lehmann, HC; Müller, C; Wiesen, MHJ | 1 |
| Imai, S; Iwamitsu, Y; Koyanagi, M; Matsubara, K; Matsumoto, M; Moriya, A; Nakagawa, S; Nakagawa, T; Nakazato, Y; Ogihara, T; Saigo, M; Yonezawa, A | 1 |
| Bagues, A; Girón, R; Goicoechea, C; Martín-Fontelles, MI; Paniagua, N; Sánchez-Robles, EM | 1 |
| Fujitani, M; Fukuyama, H; Hatanaka, S; Hiramoto, S; Kanto, A; Kawabata, A; Koizumi, Y; Miyamoto, T; Sekiguchi, F; Tsubota, M | 1 |
| Bartolini, F; Burgos, A; Galindo, SE; Grueber, WB; Hammond, LA; Kumar, A; Lucas, T; Pero, ME; Shin, GJ | 1 |
| Agalave, NM; Burton, MD; Jeong, HS; Mody, PH; Szabo-Pardi, TA | 1 |
| Bentley, J; Berthemy, A; Bosanac, T; Boyce, S; Brearley, A; Danker, K; Devraj, R; Engber, T; Hermann, M; Hughes, RO; Kopatz, J; Krauss, R; Young, K | 1 |
| Adachi, Y; Gondou, N; Hattori, M; Horisawa, N; Iwata, H; Kataoka, A; Kobara, M; Kotani, H; Mori, M; Sawaki, M; Sugino, K; Takahata, C; Terada, M; Yoshimura, A | 1 |
| Chou, PR; Huang, SH; Kan, JY; Lo, JJ; Lu, CY; Wang, SH; Wu, SH | 1 |
| Segal, RA; Silagi, ES | 1 |
| Cao, J; Li, H; Li, Z; Liu, J; Liu, X; Ma, D; Wang, X; Zhao, S | 1 |
| Hashimoto, H; Kawazoe, H; Nakamura, T; Shimanuki, Y; Terakado, H; Udagawa, R; Uozumi, R; Watabe, D; Yamaguchi, M | 1 |
| Kim, HS; Lee, M; Lee, N; Lee, S; Paik, H; Park, SJ; Yim, GW | 1 |
| Fiore, NT; Goldstein, D; Keating, BA; Lees, JG; Livni, L; Moalem-Taylor, G | 1 |
| Abdelfattah, NM; Elnahass, Y; Sabri, NA; Solayman, MH | 1 |
| Cleenewerk, L; Eijkelkamp, N; Hiensch, AE; May, AM; Vermeer, CJC | 1 |
| Chang, H; Deng, W; Lin, X; Liu, C; Liu, F; Liu, Z; Zhang, X; Zhao, C; Zhong, S; Zhou, Z | 1 |
| Chambers, C; Chen, A; Eurich, DT; Ha, V; McCall, M; Sawyer, MB; Youn, S | 1 |
| Egashira, N; Inoue, M; Kawashiri, T; Kobayashi, D; Kudamatsu, H; Mine, K; Mori, K; Shimazoe, T; Uchida, M; Ushio, S | 1 |
| Brenner, C; Hamity, MV; Hammond, DL; Schmidt, MS; Walder, RY; White, SR | 1 |
| Chang, JY; Chang, LY; Chen, LH; Chen, YF; Shen, MR; Wu, PY; Yeh, YM | 1 |
| Fujiwara, Y; Hamada, A; Hasegawa, J; Hashimoto, K; Ikeda, K; Kawabata, H; Nishizawa, D; Ozaki, Y; Shimizu, C; Shimomura, A; Takano, T; Tamura, K; Tamura, N; Tanabe, Y; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Hattori, M; Ito, H; Kawakami, M; Matsuo, M; Takahashi, N; Takemura, Y; Yamazaki, M | 1 |
| Eadens, M; Erlichman, C; Goetz, MP; Haddad, T; Lupu, R; Molina, J; Qin, R; Satele, D | 1 |
| Falconer, D; Höke, A; Reed, N; Turkiew, E | 1 |
| Duggett, NA; Flatters, SJL; Griffiths, LA | 1 |
| Beutler, AS; Dentchev, T; Dockter, T; Fruth, B; Lafky, JM; Le-Lindqwister, NA; Loprinzi, CL; Pachman, DR; Ruddy, KJ; Sikov, WM; Staff, N; Ta, LE; Zekan, PJ | 1 |
| Hayashi, T; Irie, K; Kimura, N; Kochi, A; Matsuo, K; Mishima, K; Myose, T; Nakamura, Y; Nakano, T; Sano, K; Satho, T; Takase, Y; Yamashita, Y | 1 |
| Barry, WT; Gobburu, JV; Gray, E; Hudis, C; Lad, TE; Lyss, AP; Mehrotra, S; Moreno-Aspitia, A; Overmoyer, B; Ratain, MJ; Rugo, H; Sharma, MR; Toppmeyer, DL; Valasco, M; Winer, EP; Wu, K | 1 |
| Aaronson, NK; Abyzov, A; Banck, MS; Beutler, AS; Dorsey, SG; Kanwar, R; Lavoie Smith, EM; Le-Rademacher, J; Loprinzi, CL; Pachman, DR; Qin, R; Ruddy, KJ; Seisler, D; Sloan, J | 1 |
| Maloney, A; Relias, V; Saif, MW; Smith, MH | 1 |
| Calixto, JB; Costa, R; Freitas, CS; Manjavachi, MN; Matias, DO; Passos, GF; Segat, GC | 1 |
| Moeller, M; Moore, HCF; Mustafa Ali, M; Rybicki, L | 1 |
| Akiyama, F; Fukada, I; Horii, R; Ito, Y; Iwase, T; Kobayashi, K; Ohno, S; Shibayama, T; Takahashi, S | 1 |
| Bagdas, D; Bigbee, JW; Chen, ZJ; Damaj, MI; Del Fabbro, E; Fang, X; Gewirtz, DA; Kyte, SL; Lichtman, AH; Meade, JA; Schurman, LD; Toma, W | 1 |
| Apellániz, MV; Riera, P; Salazar, J | 1 |
| Bai, CM; Cheng, YJ; Dou, XL; Luo, F; Ma, SQ; Mai, YL; Shao, YJ; Sun, Z; Wang, YY; Zhang, B; Zhou, N | 1 |
| Berg, KA; Chavera, TS; Clarke, WP; LoCoco, PM; Risinger, AL; Smith, HR | 1 |
| Ishii, N; Miura, A; Nakazato, M; Shiomi, K; Tsubouchi, H; Ueno, H; Yanagi, S | 1 |
| Alberti, P; Arnold, WD; Cavaletti, G; Chen, M; Chiorazzi, A; Chodisetty, V; Costa, O; de Bruijn, P; Florea, T; Gibson, AA; Hong, KW; Hu, S; Huang, KM; Leblanc, AF; Lustberg, MB; Mathijssen, RH; Pioso, MS; Reinbolt, RE; Sparreboom, A; Sprowl, JA; Sucheston-Campbell, LE | 1 |
| Cheng, X; Dougherty, PM; Heijnen, CJ; Huo, X; Kavelaars, A; Li, Y; Mei, F; Singhmar, P | 1 |
| Cheriyan, BV; Kadhirvelu, P; Nadipelly, J; Sayeli, V; Shanmugasundaram, J; Subramanian, V | 1 |
| Beaumont, JL; Griffiths, C; Kwon, N; Paice, JA | 1 |
| Fox, DA; Huang, P; Li, Y; Lin, F; Rosenquist, R; Saunders, TL; Xie, M; Xu, J; Zhang, L | 1 |
| Allen, JA; Gradishar, W; Hodges, JS; Raizer, J; Robertson, J | 1 |
| Brazill, JM; Cruz, B; Zhai, RG; Zhu, Y | 1 |
| Iżycka, N; Kapoła-Czyż, J; Lorek, J; Magnowska, M; Nowak-Markwitz, E; Romała, A; Spaczyński, M | 1 |
| Arai, H; Hamabe, Y; Hanai, A; Imai, S; Ishiguro, H; Nakagawa, T; Sozu, T; Toi, M; Tsuboyama, T; Tsuda, M; Yano, I | 1 |
| Bauerschlag, D; Kratzenstein, S; Maass, N; Mundhenke, C; Röcken, C; Schmidt, T; Vollmers, PL | 1 |
| Hayes, DF; Henry, NL; Hertz, DL; Kim, JH; Smith, EML; Stringer, KA; Sun, Y; Vangipuram, K; Yeomans, L | 1 |
| Duggett, NA; Flatters, SJL; Griffiths, LA; Pitcher, AL | 1 |
| Balko, RA; Grudem, ME; Hendrickson, AW; Jatoi, A; Klampe, CM | 1 |
| Bao, T; Blinder, VS; Chen, X; Dickler, MN; Li, Q; Mao, JJ; Piulson, L; Robson, ME; Seidman, AD; Vahdat, LT; Vertosick, E; Vickers, AJ; Zhi, WI | 1 |
| Bandapalli, OR; Campo, C; da Silva Filho, MI; Försti, A; Goldschmidt, H; Hemminki, K; Mahmoudpour, SH; Merz, M | 1 |
| Au, NPB; Chine, VB; Kumar, G; Ma, CHE | 1 |
| Abrams, G; Chesney, M; Conley, YP; Hammer, M; Kober, KM; Levine, JD; Mastick, J; Mazor, M; Miaskowski, C; Olshen, A; Paul, SM; Schumacher, M; Smoot, B | 1 |
| Domoto, R; Kawabata, A; Nakashima, K; Nishibori, M; Sekiguchi, F; Tsubota, M; Wake, H; Yamanishi, H; Yamasoba, D | 1 |
| Boujedaini, N; Mensah-Nyagan, AG; Meyer, L; Patte-Mensah, C; Vitet, L | 1 |
| Asghari Jafarabadi, M; Esfahani, A; Fathifar, Z; Ghoreishi, Z; Goodman, KA; Keshavarz, S | 1 |
| Imano, M; Kato, N; Koumoto, YI; Matsumoto, M; Nishida, S; Satou, T; Takeda, T; Tsubaki, M; Yasuhara, S | 1 |
| Albadri, S; Alberio, L; Barsotti, N; Beltrame, M; Bercier, V; Boender, AJ; Colecraft, HM; Contestabile, A; Del Bene, F; Di Luca, M; Ji, Y; Khanna, R; Kukovetz, K; Locarno, A; Luo, S; Marcello, E; Moleri, S; Moroni, A; Moutal, A; Pasqualetti, M; Pelucchi, S; Porro, A; Romani, G; Romano, E; Saponaro, A; Simeoni, F; Thiel, G; Tonini, R | 1 |
| Albrecht, TL; Beebe-Dimmer, JL; Greenwald, MK; Ruterbusch, JJ; Schwartz, AG; Simon, MS | 1 |
| Choi, JH; Choi, YH; Huh, G; Kim, YT; Lee, SH; Paik, WH; Ryu, JK; You, MS | 1 |
| Apellaniz-Ruiz, M; Calsina, B; Calvo, I; Cascón, A; Castelo, B; Curras, M; García-Donas, J; Guerra, E; Gutiérrez-Gutiérrez, G; Inglada-Pérez, L; Letón, R; Merino, M; Montero-Conde, C; Remacha, L; Robledo, M; Rodríguez-Antona, C; Roldán-Romero, JM; Sánchez-Barroso, L; Santos, M; Sereno, M | 1 |
| Berta, T; Lee, SH; Tonello, R | 1 |
| Dang, D; Frost, JA; Li, J; Li, L; Yang, Q; Zuo, Y | 1 |
| Bhatia, A; Chakrabarti, A; Kumari, P; Saha, L; Singh, J; Singh, N | 1 |
| Azoulay, D; Leibovici, A; Sharon, R | 1 |
| Boucher, M; Cook, JC; Fenyk-Melody, J; Liu, CN; Mechanic, J; Pardo, ID; Peng, Q; Schaevitz, L; Shoieb, A; Somps, C; Vitsky, A | 1 |
| Dantzer, R; Edralin, JD; Heijnen, CJ; Kavelaars, A; Laumet, G | 1 |
| Agapito, G; Altomare, E; Arbitrio, M; Arpino, G; Cannataro, M; Caracciolo, D; Di Martino, MT; Fabiani, F; Galeano, T; Grillone, F; Iuliano, E; Santini, D; Scionti, F; Staropoli, N; Tagliaferri, P; Tassone, P | 1 |
| Barry, BK; Goldstein, D; Grimison, P; Horvath, L; Li, T; Marthick, M; McCrary, JM; Park, SB; Sandler, CX; Timmins, HC | 1 |
| Aghili, M; Akrami, S; Esmati, E; Ghalehtaki, R; Kalaghchi, B; Mousavi, N; Sotoudeh, S; Zare, M | 1 |
| Beh, ST; Chang, WW; Chen, LT; Kuo, YM; Liao, LD; Tsai, CH; Tsao, CH; Wilder-Smith, E | 1 |
| Albain, KS; Baltay, M; Barry, WT; Burstein, HJ; Carey, LA; Dang, CT; Dillon, DA; Ellis, MJ; Fuhrman, K; Guo, H; Hudis, CA; Krop, IE; Marcom, PK; Moy, B; Overmoyer, B; Partridge, AH; Pernas, S; Ritterhouse, L; Rugo, HS; Schneider, BP; Shapira, I; Shen, F; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, DA | 1 |
| Goldstein, D; McCrary, JM; Park, SB; Tan, AC; Trinh, T | 1 |
| Deshpande, K; Garbuzenko, OB; Kagan, L; Lee, JB; Minko, T; Zang, X | 1 |
| Araújo, SB; Calixto, JB; Costa, R; Fernandes, ES; Manjavachi, MN; Passos, GF; Pontes, JP; Trevisan, G | 1 |
| Anders, CK; Basch, E; Carey, LA; Choi, SK; Deal, AM; Dees, EC; Jolly, TA; Karuturi, MS; Kimmick, GG; Lee, JT; Muss, HB; Nyrop, KA; Reeder-Hayes, KE; Reeve, BB; Reinbolt, RE; Shachar, SS; Speca, JC; Wood, WA | 1 |
| Cai, W; Dong, J; Feng, Y; Guo, X; Li, H; Sun, H; Wang, P; Zhou, Y; Zhuang, R | 1 |
| Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, S; Park, YH; Sohn, J | 1 |
| Andoh, T; Bai, Y; Ge, Y; Hanazawa, S; Hou, Z; Kato, M; Komatsu, K; Maesaka, M; Toume, K; Yu, H | 1 |
| Bang, S; He, Q; Huh, Y; Ji, RR; Luo, X; Matsuda, M; Zhang, L | 1 |
| Bagdas, D; Bigbee, JW; Cantwell, L; Chen, ZJ; Damaj, MI; Del Fabbro, E; Gewirtz, DA; Jackson, A; Kulkarni, A; Kyte, SL; Meade, JA; Papke, RL; Rahman, F; Thakur, GA; Toma, W | 1 |
| Hashimoto, T; Inamoto, T; Katayama, T; Kato, H; Kato, T; Kikawa, Y; Mizuno, Y; Ogura, N; Okuno, T; Sugie, T; Takahara, S; Takuwa, H; Tanaka, S; Tsuyuki, S; Yamagami, K; Yamashiro, H; Yamauchi, A; Yoshibayashi, H | 1 |
| Hasegawa, R; Imaizumi, H; Iwai, T; Kaneko, T; Kawaguchi, Y; Kida, M; Koizumi, W; Kurosu, T; Matsumoto, T; Miyata, E; Ohno, T; Okuwaki, K; Uehara, K; Watanabe, M; Yamauchi, H | 1 |
| Hama, T; Horai, T; Kawakami, K; Kizu, J; Nishio, M; Ohtani, T; Shibata, K; Taguchi, K; Takiguchi, T; Tunoda, T | 1 |
| Hosokawa, T; Kanbayashi, Y; Kitawaki, J; Taguchi, T | 1 |
| Carmeliet, P; Lambrechts, D; Meert, T; Nuydens, R; Peeraer, E; Pintelon, I; Poesen, K; Shibuya, M; Timmermans, JP; Verheyen, A | 1 |
| Farah, MH; Littlefield, BA; Nomoto, K; Slusher, BS; Wozniak, KM; Wu, Y | 1 |
| Brady, ST; Feinstein, SC; Jordan, MA; LaPointe, NE; Morfini, G; Wilson, L | 1 |
| Boyette-Davis, JA; Dougherty, PM; Kosturakis, AK; Li, Y; Walters, ET; Yoon, SY; Zhang, H | 1 |
| Dana, R; Downs, H; Ferrari, G; Nallasamy, N; Oaklander, AL | 1 |
| Avall-Lundqvist, E; González-Neira, A; Gréen, H; Hjerpe, E; Inglada-Pérez, L; Jara, C; Leandro-García, LJ; Leskelä, S; Mielgo, X; Pita, G; Robledo, M; Rodríguez-Antona, C | 1 |
| Kudlowitz, D; Muggia, F | 1 |
| Egashira, N; Oishi, R | 1 |
| DeMichele, A; Farrar, JT; Hennessy, S; Mao, JJ; Sammel, MD; Speck, RM; Stineman, MG | 1 |
| Itabashi, T; Kashiwaba, M; Kudo, K; Nihei, S; Sato, J; Takahashi, K | 1 |
| Mensah-Nyagan, AG; Meyer, L; Patte-Mensah, C; Taleb, O | 1 |
| Day, JM; Foster, PA; Kasprzyk, PG; Meyer-Losic, F; Newman, SP; Purohit, A; Reed, MJ | 1 |
| Fukuoka, T; Funakoshi, K; Goto, T; Kamiya, Y; Miyazaki, T; Nakahashi, Y; Ogawa, K; Tojo, K; Uchimoto, K | 1 |
| Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C | 1 |
| Baldwin, RM; Chhibber, A; Hudis, CA; Kroetz, DL; Kubo, M; Li, M; McLeod, HL; Mefford, J; Nakamura, Y; Owzar, K; Pendergrass, SA; Plenge, RM; Ratain, MJ; Ritchie, MD; Shulman, LN; Stahl, EA; Winer, EP; Witte, JS; Zembutsu, H | 1 |
| Dougherty, PM; Zhang, H | 1 |
| Abraham, JE; Bowden, SJ; Burns, R; Caldas, C; Dorling, L; Dunn, JA; Earl, HM; Guo, Q; Hardy, R; Hiller, L; Ingle, S; Jones, L; Pharoah, PP; Poole, CJ; Tyrer, J; Vallier, AL | 1 |
| Höke, A; Ray, M | 1 |
| Adams, PT; Atherton, PJ; Behrens, RJ; Dockter, TJ; Haluska, P; Leal, AD; Loprinzi, CL; Qin, R; Tiber, CH; Watanaboonyakhet, P; Weiss, M | 1 |
| Mazzocato, C | 1 |
| Hsieh, YL; Hu, ME; Ko, MH; Lan, CT; Tseng, TJ | 1 |
| Au, NP; Fang, Y; Lai, KW; Ma, CH; Xi, N | 1 |
| Cui, Y; Huang, ZZ; Li, D; Li, YY; Liu, CC; Xin, WJ; Zhang, WW; Zhu, HQ | 1 |
| Carey, LA; Clark, LS; Dees, EC; Drobish, A; Hertz, DL; Jack, J; McLeod, HL; Motsinger-Reif, AA; Roy, S | 1 |
| Dougherty, PM; Jawad, AB; Kosturakis, AK; Li, Y; Zhang, H | 1 |
| da Silva Simão, DA; de Paula Lima, ED; Souza, RS; Teixeira, AL | 1 |
| Cleeland, C; Heijnen, CJ; Huo, XJ; Kavelaars, A; Krukowski, K; Mao-Ying, QL; Price, TJ; Zhou, W | 1 |
| De Kerckhove, C; De Kerckhove, M; Haraguchi, M; Inoue, K; Irie, J; Izumida, R; Kitajima, M; Kosaka, M; Matsuda, S; Mine, T; Ohno, T; Shinichiro, I; Tanaka, T; Tokai, H; Yoshioka, H | 1 |
| Futagami, M; Hirakawa, H; Matsumura, Y; Mizunuma, H; Shigeto, T; Yokoyama, Y | 1 |
| Masocha, W | 1 |
| Apellániz-Ruiz, M; Calvo, I; Cascón, A; Castelo, B; García-Donás, J; García-Estévez, L; Guerra, E; Gutiérrez-Gutiérrez, G; Ingelman-Sundberg, M; Johansson, I; Leandro-García, LJ; Lee, MY; Robledo, M; Rodríguez-Antona, C; Sánchez-Barroso, L; Sereno, M | 1 |
| Fujiwara, S; Kanemura, M; Ohmichi, M; Ono, YJ; Sasaki, H; Tanaka, T; Tanaka, Y; Terai, Y; Tsunetoh, S | 1 |
| Cui, Y; Huang, ZZ; Li, D; Ling, YZ; Wei, JY; Xin, WJ; Zhang, XZ; Zhu, HQ | 1 |
| Burger, RA; Chase, DM; Foss, CD; Huang, H; Monk, BJ; Wenzel, LB | 1 |
| Friedlander, ML; Kiernan, MC; Krishnan, AV; Kwok, JB; Lewis, CR; Lin, CS; Loy, CT; Park, SB | 1 |
| Banck, MS; Beutler, AS; Boora, G; Kanwar, R; Kulkarni, AA; Le-Lindqwister, N; Loprinzi, CL; Ruddy, KJ; Therneau, TM | 1 |
| Egawa-Takata, T; Fujita, M; Isobe, A; Kimura, T; Kobayashi, E; Mabuchi, S; Matsuzaki, S; Otake, A; Sawada, K; Ueda, Y; Yoshino, K | 1 |
| Hoke, A; Kim, S; Park, JS | 1 |
| Conesa, MÁ; de la Morena Barrio, P; de la Peña, FA; García-Garre, E; García-Martínez, E; González-Billalabeitia, E; Poves, MZ; Urrego, E; Vicente, V | 1 |
| Ding, W; Li, J; Li, Y; Wang, X | 1 |
| Ichiba, Y; Kajiume, S; Kiba, T; Morii, N; Mura, T; Nagashima, S; Ogawa, Y; Okada, Y; Takahashi, H; Yamashiro, H | 1 |
| Gold, MS; Yilmaz, E | 2 |
| Chung, S; Delaney, SM; Dolan, ME; Gorsic, LK; Komatsu, M; Kroetz, DL; Kubo, M; Low, SK; Nakamura, Y; Takahashi, A; Wheeler, HE; Wing, C; Zhang, W | 1 |
| Cassidy, RM; Colomand, CM; Dougherty, PM; Harrison, DS; Jawad, AB; Kennamer-Chapman, RM; Kosturakis, AK; Li, Y; Zhang, H | 1 |
| Flatters, SJ; Griffiths, LA | 1 |
| Banck, MS; Behrens, RJ; Beutler, AS; Beyerlein, P; Boora, GK; Kanwar, R; Kulkarni, AA; Loprinzi, CL; Lynch, CA; Pleticha, J; Qin, R; Ruddy, KJ; Züchner, S | 1 |
| Atherton, PJ; Lafky, J; Loprinzi, CL; Pachman, DR; Ruddy, KJ; Seisler, D; Shinde, SS; Soori, G | 1 |
| Alecu, I; Bielawski, J; Ernst, D; Hornemann, T; Kistner-Griffin, E; Kornhauser, D; Kramer, R; Othman, A; Spassieva, S | 1 |
| Azoulay, D; Braester, A; Goldberg, H; Gross, B; Leibovici, A; Shaoul, E; Sharoni, R | 1 |
| Chang, JY; Chang, LY; Chen, LH; Chen, YF; Lee, MY; Shen, MR; Sun, YT | 1 |
| Bober, BG; Shah, SB | 1 |
| Heijnen, CJ; Huo, X; Kavelaars, A; Krukowski, K; Nijboer, CH | 1 |
| Bu, Z; Peng, L; Ye, X; Zhao, Q; Zhou, Y | 1 |
| Brewer, JR; Dolan, ME; Fleming, GF; Morrison, G | 1 |
| Ferrara, S; Goldstein, D; Greeno, E; Liu, H; Lu, B; Macarulla, T; Moore, M; Pilot, R; Ramanathan, RK; Tortora, G; Von Hoff, DD | 1 |
| Abe, K; Chiba, T; Kambe, T; Kawakami, K; Koizumi, N; Oka, Y; Taguchi, K; Utsunomiya, I | 1 |
| Benbow, SJ; Cook, BM; Feinstein, SC; Jordan, MA; Littlefield, BA; Reifert, J; Slusher, BS; Wilson, L; Wozniak, KM | 1 |
| Abyzov, A; Banck, MS; Beutler, AS; Boora, GK; Kanwar, R; Kulkarni, AA; Loprinzi, CL; Ruddy, KJ; Sloan, J | 1 |
| Hiraoka, M; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N | 1 |
| Ali, YO; Hohmann, AG; Lu, HC; Slivicki, RA | 1 |
| Taguchi, K | 1 |
| Fehrenbacher, JC; Gracias, NG; Pittman, SK | 1 |
| Chen, H; Li, D; Luo, XH; Sun, Y; Xia, W; Xiong, YC | 1 |
| Albrecht, PJ; de Carvalho-Barbosa, M; Dougherty, PM; Heijnen, CJ; Kavelaars, A; Li, Y; Zhang, H | 1 |
| Cetinkaya-Fisgin, A; Hoke, A; Joo, MG; Ozturk, C; Ping, X; Thakor, NV; Yang, IH | 1 |
| DesJardins, C; Lai, G; Littlefield, BA; Nomoto, K; Reyderman, L; Slusher, BS; Vornov, JJ; Wong, N; Wozniak, KM; Wu, Y; Yu, Y | 1 |
| Egashira, N; Kaname, T; Kawashiri, T; Shiraishi, H; Tsutsumi, K | 1 |
| de Santis, V; Duggett, NA; Flatters, SJ; Griffiths, LA; McKenna, OE; Mokori, EB; Yongsanguanchai, N | 1 |
| Farah, MH; Rammelkamp, Z; Slusher, AB; Slusher, BS; Tasnim, A; Wozniak, K | 1 |
| Ishikura, H; Kamitani, N; Kawabata, A; Kawaishi, Y; Liu, K; Nishibori, M; Nishida, T; Sekiguchi, F; Tsubota, M; Yamanishi, H | 1 |
| Farah, MH; Feinstein, S; Jordan, MA; Slusher, BS; Smith, JA; Smiyun, G; Wilson, L; Wozniak, KM | 1 |
| Beutler, AS; Cavaletti, G; Dougherty, PM; Grothey, A; Kaggal, S; Lafky, JM; Loprinzi, CL; Novotny, P; Pachman, DR; Qin, R; Ruddy, KJ; Seisler, D; Smith, EM; Staff, NP; Ta, LE; Wagner-Johnston, ND | 1 |
| Asuncion, BR; Bandla, A; Fazreen, Z; Goh, BC; Ho, J; Hoppe, MM; Jeyasekharan, AD; Kumarakulasinghe, NB; Lee, SC; Lim, JS; Ow, SG; Pang, B; Poh, LM; Putti, TC; Soong, RC; Sundar, R; Tan, DS; Tan, SS; Wilder-Smith, EP | 1 |
| Foroud, T; Gardner, L; Jiang, G; Lai, D; Li, L; Miller, KD; O'Neill, A; Radovich, M; Schneider, BP; Shen, F; Sledge, GW; Sparano, JA; Xue, G | 1 |
| Boven, E; Frederiks, CN; Guchelaar, HJ; Honkoop, AH; Lam, SW; van der Straaten, T | 1 |
| Block, MS; Botero, JP; Deering, E; Dockter, TJ; Fields, AP; Grudem, ME; Jatoi, A; Kasi, PM; Mansfield, AS; Okuno, SH; Smith, DR; Tan, A; Villasboas, JC | 1 |
| Cassidy, RM; Dougherty, PM; Edwards, DD; Harrison, DS; Johansson, CA; Kosturakis, AK; Li, Y; North, RY; Rhines, LD; Tatsui, CE; Zhang, H | 1 |
| Ando, Y; Goto, H; Kikumori, T; Maeda, O; Matsuoka, A; Mizutani, T; Nakano, Y; Tsunoda, N | 1 |
| Hayashi, S; Ikeda, H; Ikegami, M; Kai, M; Kamei, J; Nakanishi, Y; Sakai, A | 1 |
| Seagle, BL; Shahabi, S | 1 |
| Agergaard, K; Bergmann, TK; Brøsen, K; Hallas, J; Hassel, RE; Jørgensen, TL; Mau-Sørensen, M; Milo, M; Pedersen, JW; Pottegård, A; Poulsen, SH; Stage, TB; Steffensen, KD | 1 |
| Cohen, L; Driver, L; Eng, C; Lopez, G; Lyle, R; McQuade, J; Novy, D; Prinsloo, S; Ramondetta, L | 1 |
| Barton, D; Grothey, A; Kottschade, L; Loprinzi, C; Wolf, S | 1 |
| Futagawa, T; Kuchiiwa, S; Masuda, S; Nishida, K; Oiso, S; Takeda, Y; Yamada, K | 1 |
| Camozzi, F; Lauria, G; Melli, G; Podini, P; Quattrini, A; Taiana, M; Taroni, F; Triolo, D | 1 |
| Gu, Y; Shu, Y; Xu, Q | 1 |
| Egashira, N; Ikegami, Y; Itoh, Y; Kawashiri, T; Oishi, R; Shimazoe, T; Yano, T; Yoshimura, M | 1 |
| Aranishi, T; Hausheer, FH; Hisamatsu, K; Kuroi, K; Masuda, N; Morita, S; Ohashi, Y; Ohsumi, S; Shimozuma, K; Takeuchi, A | 1 |
| Avezza, F; Bossi, M; Canta, A; Carozzi, V; Cavaletti, G; Ceresa, C; Chiorazzi, A; Crippa, L; Gilardini, A; Nicolini, G; Oggioni, N; Rodriguez-Menendez, V | 1 |
| Katsuura, M; Kurokawa, N; Miwa, Y; Murai, T; Noguchi, S; Oishi, M; Okamoto, Y; Taguchi, T; Ueda, M; Uejima, E; Yamamoto, T | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Egoshi, K; Fukasawa, S; Hamano, M; Ichikawa, T; Imamura, Y; Maruoka, M; Miyasaka, K; Nakamura, K; Nihei, N; Sazuka, T; Suyama, T; Ueda, T | 1 |
| Agthong, S; Chentanez, V; Duangmardphon, N; Huanmanop, T; Kaewsema, A; Maneesri, S; Thanomsridejchai, N | 1 |
| Belisle, JA; Engle, DB; Gubbels, JA; Hutson, PR; Kushner, DM; Patankar, MS; Petrie, SE | 1 |
| Andoh, T; Fujita, M; Gauchan, P; Ikeda, K; Kato, A; Kuraishi, Y; Sasaki, A | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Bordin, V; Bozzoni, S; Caldiera, S; Codecà, C; Di Maria, G; Ferrari, D; Fiore, J; Floriani, I; Foa, P; Luciani, A; Zonato, S | 1 |
| Boyette-Davis, JA; Fuchs, PN | 1 |
| Andras, M; Dabby, R; Fishman, A; Gadoth, N; Karmon, Y; Levavi, H; Levi, T; Loven, D; Sabach, G; Zart, R | 1 |
| Avallone, A; Chiuri, VE; Cioffi, R; Comella, P; Costanzo, R; De Cataldis, G; Filippelli, G; Franco, L; Greco, E; Maiorino, L; Mancarella, S; Palmeri, L; Putzu, C; Vessia, G | 1 |
| Buzdar, A; Morrow, PK; Reyes-Gibby, CC; Shete, S | 1 |
| Argyriou, AA | 1 |
| Anami, S; Fujii, C; Fujino, M; Fujita, Y; Furukawa, H; Imamura, H; Kishimoto, T; Matsumura, T; Miyazaki, Y; Sumita, R; Takada, N; Yasui, Y | 1 |
| Akiya, T; Higuchi, K; Koizumi, W; Nakayama, N; Sakuyama, T; Sasaki, T; Sato, A; Sekikawa, T; Tanabe, S; Yamaguchi, K | 1 |
| Fukushima, M; Higashiyama, T; Hirokawa, M; Ito, Y; Matsuzuka, F; Miya, A; Miyauchi, A; Uruno, T | 1 |
| Abdi, S; Gwak, YS; Kim, HK; Zhang, YP | 1 |
| Burgos, E; Goicoechea, C; Martín, MI; Pascual, D | 1 |
| Ebara, K; Hayashi, H; Ichimura, E; Kobayashi, H; Mashiba, H; Nagai, D; Nakamura, I; Nishikawa, K; Okamoto, K; Wake, N | 1 |
| Astruc-Diaz, F; Craig, S; Diaz, P; Munoz, E; Naguib, M; Xu, JJ | 1 |
| Colvin, LA; Fallon, MT; Fleetwood-Walker, SM; Mackean, MJ; Mitchell, R; Storey, DJ | 1 |
| Fracasso, PM; Garcia, AA; Knight, D; Mannel, RS; Muggia, F; Sill, MW; Swensen, R; Tiersten, AD; Warshal, DP | 1 |
| Bao, YJ; Hou, W; Hua, BJ; Xu, WR | 1 |
| Fitzgerald, GK; Hile, ES; Studenski, SA | 1 |
| Bossi, M; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Marmiroli, P; Meregalli, C; Oggioni, N; Sala, B | 1 |
| Cella, D; De Geest, K; Homesley, HD; Huang, H; Lee, R; Montag, A; Salani, R; Spirtos, NM | 1 |
| Campbell, KL; McNeely, ML | 1 |
| Kawamata, T; Kiya, T; Namiki, A; Yamakage, M | 1 |
| Awad, D; Brafman, L; Crew, KD; Fuentes, D; Hershman, DL; Kranwinkel, G; Wang, A; Weimer, LH | 1 |
| Egashira, N; Kawashiri, T; Mihara, Y; Mishima, K; Oishi, R; Tatsushima, Y; Yano, T | 1 |
| Kip, K; Overcash, J; Tofthagen, C | 1 |
| Burger, KN; Dakhil, SR; Jaslowski, AJ; Kamal, A; Lachance, DH; Le-Lindqwister, NA; Loprinzi, CL; Novotny, PJ; Reeves, BN; Sloan, JA; Soori, GS; Wolf, SL | 1 |
| Bento, AF; Calixto, JB; Costa, R; Dutra, RC; Malinsky, FR; Manjavachi, MN; Motta, EM; Pesquero, JB | 1 |
| Chen, X; Green, PG; Levine, JD | 1 |
| Fujimoto, S; Fukuda, T; Furihata, T; Hase, I; Ishii, Y; Kikkawa, Y; Miyoshi, M; Okazaki, K; Takizawa, H; Yamada, I | 1 |
| Neelakantan, H; Ramirez, MD; Walker, EA; Ward, SJ | 1 |
| Blagden, S; Gabra, H; Graham, J; Sharma, R | 1 |
| Bacon, M; Brown, C; Donadello, N; Friedlander, M; Gebski, V; Gurney, H; Lee, CK; Lord, S; Maenpaa, J; Meier, W; Petru, E; Pujade-Lauraine, E; Reed, N; Simes, RJ; Sorio, R; Tulunay, G | 1 |
| Honda, K; Imaishi, H; Kamura, T; Takemoto, S; Terada, A; Ushijima, K; Wada, H | 1 |
| Berman, BM; Lao, L; Li, A; Meng, X; Ren, K; Tan, M; Xin, J; Zhang, RX; Zhang, Y | 1 |
| Chen, C; Lu, Y; Wang, L; Xu, F; Xu, S; Zhang, H; Zhou, X | 1 |
| Egashira, N; Kawashiri, T; Masuguchi, K; Oishi, R; Ushio, S; Yamashita, Y | 1 |
| Alimoradi, H; Bakhtiarian, A; Dehpour, AR; Hadian, MR; Hassanzadeh, G; Mehr, SE; Pourmohammadi, N; Sharifzadeh, M | 1 |
| Fidanboylu, M; Flatters, SJ; Griffiths, LA | 1 |
| Aranda Aguilar, E; de la Haba-Rodríguez, JR; Gómez-España, MA; Ortiz-Morales, MJ | 1 |
| Bennett, GJ; Meert, TF; Nuydens, R; Xiao, WH; Zheng, FY; Zheng, H | 1 |
| Ando, M; Fujiwara, Y; Harano, K; Hashimoto, K; Hirakawa, A; Katsumata, N; Kinoshita, T; Shimizu, C; Tamura, K; Tanabe, Y; Yonemori, K; Yunokawa, M | 1 |
| Barg, FK; DeMichele, A; Farrar, JT; Hennessy, S; Mao, JJ; Speck, RM; Stineman, MG | 1 |
| Benemei, S; Creminon, C; Fusi, C; Geppetti, P; Materazzi, S; Nassini, R; Nilius, B; Patacchini, R; Pedretti, P; Prenen, J | 1 |
| Aissi, M; Kubis, N; Lévy, BI; Milani, P; Osmani, K; Vignes, S; Wade, F | 1 |
| Burgos, E; Goicoechea, C; Gómez-Nicola, D; Martín, MI; Nieto-Sampedro, M; Pascual, D | 1 |
| Bie, B; Brown, DL; Cogdell, D; Craig, S; Diaz, P; Hittelman, WN; Hu, J; Naguib, M; Xu, JJ | 1 |
| Burger, KN; Dakhil, SR; Jaslowski, AJ; Kamal, A; Kelaghan, J; Lachance, DH; Le-Lindqwister, NA; Loprinzi, CL; Novotny, PJ; Reeves, BN; Sloan, JA; Soori, GS; Wolf, SL | 1 |
| Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y | 1 |
| Aranishi, T; Hausheer, FH; Katsumata, N; Kuranami, M; Kuroi, K; Makino, H; Morita, S; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takeuchi, A; Watanabe, T | 1 |
| Ami, N; Okamoto, K; Oshima, H | 1 |
| Boers, P; Gupta, RK; Mainstone, P; McNamara, B; Quintyne, KI; Wallis, F | 1 |
| Avall-Lundqvist, E; Cascón, A; Comino-Méndez, I; de Cubas, AA; Dolan, ME; Gréen, H; Inglada-Perez, L; Jara, C; Leandro-García, LJ; Leskelä, S; Maliszewska, A; Mancikova, V; Robledo, M; Rodríguez-Antona, C; Wheeler, HE | 1 |
| Cilli, M; Emionite, L; Ghignotti, M; Leandri, M; Leandri, S | 1 |
| Kang, S; Lim, MC; Lim, S; Park, JY; Park, SY; Seo, SS; Yoo, HJ | 1 |
| Baldwin, RM; Chhibber, A; Eclov, RJ; Friedman, PN; Hudis, CA; Jiang, C; Jorgenson, EM; Kroetz, DL; Kubo, M; McLeod, HL; Mefford, J; Nakamura, Y; Owzar, K; Ratain, MJ; Shulman, LN; Watson, D; Winer, EP; Witte, JS; Zembutsu, H | 1 |
| Benbow, JH; Ehrlich, BE; Erdelyi, I; Mo, M; Szigeti-Buck, K | 1 |
| Asghari Jafarabadi, M; Ayromlou, H; Darabi, M; Djalali, M; Djazayeri, A; Esfahani, A; Ghoreishi, Z; Golestan, B; Hashemzade, S; Keshavarz, SA; Montazeri, V | 1 |
| Benbow, JH; DeGray, B; Ehrlich, BE; Fan, C; Hodsdon, ME; Keeler, C; Lolis, E; Mann, T | 1 |
| Hosokawa, A; Kiba, T; Kozawa, K; Nakashima, T; Ogawa, Y; Okada, Y; Shigeta, M; Shintani, H; Taniguchi, T | 1 |
| Deng, L; Guindon, J; Hohmann, AG; Makriyannis, A; Thakur, GA; Vemuri, VK; White, FA | 1 |
| Iida, H; Matsumoto, S; Miyamoto, M; Takenaka, M; Yamaguchi, S; Yoshimura, N | 1 |
| Baldwin, RM; Cox, NJ; Dolan, ME; Gamazon, ER; Hudis, CA; Jiang, C; Kroetz, DL; Kubo, M; Nakamura, Y; Njiaju, UO; Njoku, C; Owzar, K; Ratain, MJ; Shterev, I; Shulman, LN; Watson, D; Wheeler, HE; Winer, EP; Wing, C; Zembutsu, H | 1 |
| Boyette-Davis, JA; Bruel, BM; Cata, JP; Dougherty, PM; Driver, LC; Kennedy, WR; Mooring, DL; Novy, DM; Wendelschafer-Crabb, G | 1 |
| Kawamata, T; Kiya, T | 1 |
| Kawabata, A | 1 |
| Baselga, J; Bellmunt, J; Clèries, R; Cos, J; Eres, N; Margarit, C; Murio, JE; Pérez, M; Ribas, A | 1 |
| Bakri, K; Hudgens, S; Kies, MS; Lee, JH; Peterman, A; Schell, MJ; Socinski, MA; Unger, P; Yates, S | 1 |
| Culver, DG; Davis, AA; Glass, JD; Wang, MS | 1 |
| Peltier, AC; Russell, JW | 2 |
| Bertucci, F; Chabannon, C; Conte, M; Genre, D; Gravis, G; Houvenaeghel, G; Maraninchi, D; Viens, P; Viret, F | 1 |
| Chaudhry, M; Chaudhry, V; Crawford, TO; Griffin, JW; Simmons-O'Brien, E | 1 |
| Kamura, T; Kawagoe, H; Kumagai, S; Matsuo, G; Nishida, T; Nishio, S; Ota, S; Sugiyama, T; Ushijima, K | 1 |
| Markman, M | 2 |
| Heimans, JJ; Hoekman, K; Postma, TJ; Verstappen, CC | 1 |
| Bárdos, G; Bernáth, S; Farkas, B; Jaszlits, L; Literáti-Nagy, B; Literáti-Nagy, P; Móricz, K; Rabloczky, G; Rácz, I; Sümegi, B; Tory, K | 1 |
| Chentanez, V; Panyasawad, N; Sanguanrungsirigul, S | 1 |
| Behringer, D; Berger, DP; Gerds, TA; Lange, W; Mielke, S; Mross, K; Schmidt, A; Wäsch, R | 1 |
| Rose, PG; Smrekar, M | 1 |
| Bogliun, G; Cavaletti, G; Colombo, N; Cundari, S; Fei, F; Lissoni, A; Marzorati, L; Parma, G; Piatti, M; Zanna, C; Zincone, A | 1 |
| Almadrones, L; Cella, DF; Donnelly, J; Herzog, TJ; McGuire, WP; Moore, DH; Waggoner, SE | 1 |
| Hsu, Y; Sood, AK; Sorosky, JI | 1 |
| Beamon, K; Doroshow, JH; Forman, S; Longmate, J; Margolin, K; Morgan, R; Openshaw, H; Shibata, S; Slatkin, NE; Somlo, G; Synold, TW | 1 |
| Akiyama, Y; Hotta, K; Inoue, A; Kodama, T; Kunitoh, H; Kusaba, H; Nokihara, H; Ohe, Y; Saijo, N; Sawada, M; Sekine, I; Shimoyama, T; Tamura, T; Watanabe, H; Yamamoto, N | 1 |
| Crager, SE; Mogil, JS; Smith, SB | 1 |
| Alessandri-Haber, N; Dina, OA; Levine, JD; Parada, CA; Reichling, DB; Yeh, JJ | 1 |
| Almadrones, L; Florio, CM; McGuire, DB; Tian, C; Walczak, JR | 1 |
| Bortolussi, R; La Mura, N; Lombardi, D; Scalone, S; Sorio, R; Veronesi, A | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Arné-Bès, MC | 1 |
| Dellon, AL; Livengood, MS; Maloney, CT; Swier, P; Werter, S | 1 |
| Edwards, RP; Gallion, HH; Kelley, JL; Kunschner, AJ; Sit, AS | 1 |
| Asmar, L; Dakhil, S; Friedland, DM; Gregurich, MA; Hollen, C | 1 |
| Fujii, K; Kikuchi, Y; Kita, T; Kudoh, K; Okamoto, S; Saitoh, K; Sasaki, N; Takano, M; Tanaka, S; Tode, T | 1 |
| Atkinson, R; Coleman, R; Gabra, H; Gordon, A; Hay, A; Jayson, GC; Kaye, SB; Parkin, D; Paul, J; Vasey, PA | 1 |
| Argyriou, AA; Chroni, E; Ellul, J; Iconomou, G; Kalofonos, HP; Katsoulas, G; Koutras, A; Papapetropoulos, S | 1 |
| Flaherty, K; Konkle, BA; Kramer, A; Morgan, M; O'Dwyer, PJ; Stevenson, JP; Veronese, ML | 1 |
| Argyriou, AA; Chroni, E; Iconomou, A; Iconomou, G; Kalofonos, HP; Koutras, A; Polychronopoulos, P | 1 |
| van den Bent, MJ | 1 |
| Arezzo, J; Bartley, P; Chia, M; Daly, M; Davis, ID; Green, M; Harrison, L; Kiers, L; MacGregor, L; Michael, M; Quinn, M; Rosenthal, M | 1 |
| Canta, A; Cavaletti, G; Galbiati, S; Gilardini, A; Giussani, G; Lanzani, F; Mueller, L; Nicolini, G; Persohn, E; Schoepfer, S; Scuteri, A; Traebert, M | 1 |
| Aravindan, N; Cata, JP; Chen, JH; Dougherty, PM; Shaw, AD; Weng, HR | 1 |
| Hada, T; Hara, T; Hirano, M; Hirano, Y; Kikkawa, H; Nakada, K; Nozawa, H; Oyama, K; Takagi, T | 1 |
| Balmaceda, CM; Gooch, CL; Hesdorffer, CS; Stubblefield, MD; Troxel, AB; Vahdat, LT | 1 |
| Behringer, D; Gelderblom, H; Mielke, S; Mross, K; Sparreboom, A; Steinberg, SM; Unger, C | 1 |
| Argyriou, AA; Assimakopoulos, K; Chroni, E; Gourzis, P; Iconomou, G; Kalofonos, HP; Koutras, A; Polychronopoulos, P | 1 |
| Bove, L; Jandolo, B; Pace, A | 1 |
| Beamon, K; Longmate, J; Openshaw, H; Slatkin, NE; Somlo, G; Synold, T | 1 |
| Hohmann, AG | 1 |
| Dworkin, RH; Griggs, J; Herrmann, D; Jung, BF; Oaklander, AL | 1 |
| Goicoechea, C; Martín, MI; Pascual, D; Suardíaz, M | 1 |
| Argyriou, AA; Chroni, E; Iconomou, G; Kalofonos, HP; Koutras, A; Polychronopoulos, P | 1 |
| Mielke, S; Mross, K; Sparreboom, A | 1 |
| Cata, JP; Chen, JH; Dougherty, PM; Weng, HR | 1 |
| Biamonte, R; Cartenì, G; Colucci, G; Danese, S; de Matteis, A; De Placido, S; Di Maio, M; Di Vagno, G; Febbraro, A; Gasparini, G; Lombardi, AV; Manzione, L; Marinaccio, M; Massidda, B; Nardi, M; Perrone, F; Pignata, S; Pisano, C; Scambia, G; Valerio, MR | 1 |
| Bennett, GJ; Flatters, SJ; Xiao, WH | 1 |
| Bennett, GJ; Carr, D; Cianfrocca, M; Flatters, SJ; Gillis, TA; McNicol, E; Relias, V | 1 |
| Bennett, GJ; Flatters, SJL | 1 |
| Lee, JJ; Swain, SM | 1 |
| Hald, A; Inoue, M; Matsumoto, M; Ueda, H; Xie, W | 1 |
| Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ | 1 |
| Bennett, GJ; Siau, C; Xiao, W | 1 |
| Ghilardi, JR; Jimenez-Andrade, JM; Kuskowski, MA; Mantyh, PW; Mejia, NA; Peters, CM | 1 |
| Hikino, H; Kawashima, M; Ozaki, N; Yamada, T | 1 |
| Argyriou, AA; Chroni, E; Iconomou, G; Kalofonos, HP; Koutras, A; Papapetropoulos, S; Polychronopoulos, P | 1 |
| Behringer, D; Figg, WD; Mielke, S; Mross, K; Sissung, TM; Sparreboom, A; Steinberg, SM | 1 |
| Ghilardi, JR; Jimenez-Andrade, JM; Jonas, BM; Koewler, NJ; Mantyh, PW; Peters, CM; Sevcik, MA; Wong, GY | 1 |
| Akiyama, F; Furukawa, K; Hatake, K; Horikoshi, N; Ito, Y; Kasumi, F; Mizunuma, N; Sakamoto, G; Sawaki, M; Tajiri, T; Takahashi, S | 1 |
| Isner, JM; Kirchmair, R; Kusano, K; Losordo, DW; Panagiotou, E; Ropper, AH; Schratzberger, P; Silver, M; Tietz, AB; Walter, DH; Weber, A; Weinberg, DH; Yoon, YS | 1 |
| Chavez, RA; Jekich, BM; Johnson, KW; Langer, SJ; Ledeboer, A; Leinwand, LA; Mahoney, JH; Maier, SF; Martin, D; Milligan, ED; Sloane, EM; Watkins, LR | 1 |
| Argyriou, AA; Argyriou, K; Chroni, E; Kalofonos, HP; Koutras, A; Petsas, T; Polychronopoulos, P; Xiros, N | 1 |
| Bria, E; Calabretta, F; Cuppone, F; Galiè, E; Graziano, G; Jandolo, B; Natoli, G; Nisticò, C; Pace, A; Sperduti, I; Terzoli, E; Tomao, S | 1 |
| Boehmerle, W; Ehrlich, BE; Heidrich, FM; Jordt, SE; Lee, Y; Sivula, M; Zhang, K | 1 |
| Augusto, C; Cinzia, M; Luca, G; Pietro, M; Sara, C; Scaioli, V; Sergio, C | 1 |
| Hirata, K; Ito, T; Sato, T; Takashima, T | 1 |
| Bennett, GJ; Xiao, WH | 1 |
| Connor, B; Dragunow, M; Jamieson, SM; Liu, JJ; McKeage, MJ | 1 |
| Furlow, B | 1 |
| Koike, H; Oki, Y; Sobue, G | 1 |
| Choi, BS; Robins, HI | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Bennett, GJ; Flatters, SJ; Jin, HW; Mulhern, HL; Xiao, WH | 1 |
| Azzoli, CG; Brower, M; Chia, G; Fiore, J; Hawkins, MJ; Heelan, R; Kris, MG; Miller, VA; Ng, KK; Riely, GJ; Rizvi, NA | 1 |
| Andriambeloson, E; Callizot, N; Cirillo, R; Dreano, M; Ferro, P; Glass, J; Revel, M; Vitte, PA | 1 |
| Argiris, A; Axelrod, R; Burtness, BA; Forastiere, AA; Manola, J | 1 |
| Dufresne, A; Pivot, X; Viel, E; Villanueva, C | 1 |
| Kusunoki, J; Saito, T | 1 |
| Bayo, J; Bernabé, R; Jiménez, J; Lomas, M; Lopez-Ladrón, A; Moreno, A; Ruiz, M; Salvador, J; Valero, M; Vicente, D | 1 |
| Aono, Y; Arai, T; Hidaka, T; Ieki, M; Kuraishi, Y; Nagira, K; Nakamura, T; Saito, S; Shima, T | 1 |
| Horwitz, SB; Raine, CS; Röyttä, M | 1 |
| Bentley, S; Bernard, S; Brecher, M; Graham, M; Johnston, C; Serody, J; Shea, T; Steagall, A; Vaisman, A; Wiley, J | 1 |
| Alberti, D; Arzoomanian, R; Feierabend, C; Schiller, JH; Spriggs, D; Storer, B; Tutsch, K | 2 |
| Baselga, J; Crown, JP; Currie, V; Forsythe, P; Gilewski, TA; Hakes, TB; Hudis, CA; Reichman, BS; Seidman, AD; Yao, TJ | 1 |
| Beijnen, JH; Bierhorst, F; Heimans, JJ; Huizing, MT; Mandjes, IA; Pinedo, HM; Postma, TJ; ten Bokkel Huinink, WW; Vermorken, JB; Winograd, B | 1 |
| Bonjo, CA; Comis, RL; Engstrom, PF; Johnson, S; Langer, CJ; Leighton, JC; Litwin, S; McAleer, CA; O'Dwyer, PJ; Ozols, RF | 1 |
| Capri, G; Caraceni, A; Fulfaro, F; Gianni, L; Laffranchi, A; Martini, C; Munzone, E; Spreafico, C; Tarenzi, E; Villani, F | 1 |
| Braga, M; Cavaletti, G; Tazzari, S; Tredici, G | 1 |
| Chazard, M; Corette, L; Dieras, V; Garet, F; Marty, M; Mignot, L; Morvan, F; Onetto, N; Serin, D; Tubiana, N | 1 |
| Bogliun, G; Cavaletti, G; Colombo, N; Marzola, M; Marzorati, L; Tredici, G; Zincone, A | 1 |
| Hagemeister, F; McLaughlin, P; Melnyk, A; Moore, D; North, L; Rodriguez, MA; Romaguera, J; Sarris, A; Swan, F; Younes, A | 1 |
| Donehower, RC; Rowinsky, EK | 1 |
| Einzig, AI; Kaplan, JG; Schaumburg, HH | 1 |
| Chaudhry, V; Cornblath, DR; Donehower, RC; Rowinsky, EK; Sartorius, SE | 1 |
| Calzone, K; McCauley, DL; Wicha, M | 1 |
| Foa, R; Norton, L; Seidman, AD | 1 |
| Barohn, R; Mendell, JR; New, P; Sahenk, Z | 1 |
| Chaudhry, V; Cornblath, DR; Donehower, RC; Rowinsky, EK | 1 |
| Finley, RS; Rowinsky, EK | 1 |
| Dittrich, C; Fazeny, B; Fiegl, M; Grisold, W; Huber, H; Zifko, U | 1 |
| Ikeda, M; Kodama, S; Kudo, R; Nishiya, I; Noda, K; Nozawa, S; Taketani, Y; Tanaka, K; Terashima, Y; Yajima, A | 1 |
| Arbuck, SG; Chaudhry, V; Donehower, RC; Eisenhauer, EA; Rowinsky, EK | 1 |
| Arbuck, SG; Canetta, R; Christian, MC; Onetto, N | 1 |
| Hilkens, PH; Stoter, G; van den Bent, MJ; van Putten, WL; Vecht, CJ; Verweij, J | 1 |
| Barohn, RJ; Burris, H; Jackson, CE; New, PZ; Rinaldi, D | 1 |
| Chang, AY; DeVore, R; Johnson, D | 1 |
| Anand, A; Huberman, M | 1 |
| Nishiwaki, Y; Saijo, N; Sasaki, Y; Tamura, T | 1 |
| Dreps, A; Gatzemeier, U; Heckmayer, M; Neuhauss, R; Schlüter, I; von Pawel, J; Wagner, H | 1 |
| Adams, D; Belli, L; Gottfried, M; LeCesne, A; LeChevalier, T; Pellae-Cosset, B; Ruffie, P; Tete, L | 1 |
| Bauknecht, T; Bochtler, H; Diergarten, K; du Bois, A; Köchli, O; Kreienberg, R; Kühnle, H; Lück, HJ; Meerpohl, HG; Möbus, V | 1 |
| Chao, Y; Chen, LT; Chen, YM; Chou, CM; Liu, JM; Liu, TW; Whang-Peng, J; Yu, WL | 1 |
| Jeffers, S; Muggia, FM; Parimoo, D | 1 |
| Fujii, S; Hatae, M; Ikeda, M; Isonishi, S; Izumi, R; Kodama, S; Kudo, R; Kuroshima, Y; Mori, T; Nishijima, M; Nishiya, I; Noda, K; Nozawa, S; Ogita, S; Okada, H; Ozaki, M; Satoh, I; Takahashi, T; Takeda, Y; Taketani, Y; Tamaya, T; Tanaka, K; Terashima, Y; Tokunaga, A; Yajima, A | 1 |
| Belinson, J; Connelly, E; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
| Benito, J; Colomer, R; Hidalgo, M; Paz-Ares, L | 1 |
| Amadori, D; Frassineti, GL; Gentile, A; Milandri, C; Ravaioli, A; Salzano, E; Tienghi, A; Zoli, W | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Michelotti, A; Salvadori, B; Salzano, E; Tibaldi, C | 1 |
| Gerl, A; Wilmanns, W | 1 |
| Alexander, R; Bonjo, CA; Kosierowski, R; Langer, CJ; Litwin, S; McAleer, CA; Millenson, M; O'Dwyer, P; Ozols, R | 1 |
| DeVore, R; Hande, KR; Johnson, DH; Paul, DM | 1 |
| Hanske, M; Hecker, D; Heider, A; Koschel, G; Niederle, N; von Pawel, J; Wagner, H | 1 |
| Natale, RB | 1 |
| Akerley, W | 1 |
| Athanasiadis, A; Fountzilas, G; Kosmidis, P; Mylonakis, N; Samantas, E; Skarlos, D | 1 |
| Greco, FA; Hainsworth, JD | 1 |
| Emiliani, E; Giannini, M; Marangolo, M; Rosti, G; Vertogen, B; Zumaglini, F | 1 |
| Hilkens, PH; Stoter, G; van den Bent, MJ; Vecht, CJ; Verweij, J | 1 |
| Beijnen, JH; Birkhofer, MJ; Helmerhorst, TJ; Huizing, MT; Lai, A; Rodenhuis, S; Rosing, H; Schaefers, MC; ten Bokkel Huinink, WW; van Warmerdam, LJ; Veenhof, CH | 1 |
| Gordon, AN; Matthews, CM; Nemunaitis, J; Stringer, CA; Willis, DL | 1 |
| Aloe, A; Atlante, G; Calabresi, F; Cognetti, F; De Marco, S; Iacovelli, A; Nardi, M | 1 |
| Balmaceda, C; Brasher, P; DeAngelis, LM; Forsyth, PA; Peterson, K; Seidman, AD | 1 |
| Cavalli, F; Cerny, T; de Jong, J; Goldhirsch, A; Martinelli, G; Pagani, O; Sessa, C; Zimatore, M | 1 |
| Auff, E; Berger, T; Doppelbauer, A; Huber, H; Krajnik, G; Malayeri, R; Pirker, R | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 2 |
| Curé, H; Diéras, V; Guastalla, JP; Jacquin, JP; Leduc, B; Mignot, L; Mousseau, M; Orfeuvre, H; Paraïso, D; Pujade-Lauraine, E; Tubiana-Mathieu, N; Viens, P; Vincent, P; Weber, B | 1 |
| Bauknecht, T; Costa, S; du Bois, A; Jackisch, C; Lück, HJ; Meier, W; Möbus, V; Nitz, U; Olbricht, S; Richter, B; Schröder, W; Warm, M | 1 |
| Alvarez, AM; Blajman, C; Breier, S; Cazap, E; Cóppola, FS; Ezcurdia, L; Fasce, H; Fein, L; Jovtis, SL; Lewi, D; Luchina, AM; Martínez, CA; Mickiewicz, E; Pasccón, G; Polera, J; Politi, PM; Rondinón, M; Rubio, G; Temperley, G; Triguboff, E; Uranga, G | 1 |
| Benito, D; Casado, A; Cervantes, A; del Campo, JM; Escobedo, A; Massuti, B; Mendiola, C; Moyano, A; Ojeda, B; Poveda, A | 1 |
| Bachelot, T; Biron, P; Blay, JY; Catimel, G; Chauvin, F; Droz, JP; Guastalla, JP; Merrouche, Y; Ray-Coquard, I | 1 |
| Furuse, K; Kunitoh, H; Noda, K; Ogawa, M; Saijo, N | 1 |
| Adelantado, S; González, P; Iñiguez, C; Larrodé, P; Mayordomo, JI; Morales, F; Trés, A; Yubero, A | 1 |
| Apfel, SC | 1 |
| Boyle, FM; Shenfield, GM; Wheeler, HR | 1 |
| Bolognesi, A; Bordogna, G; Canal, N; Fazio, R; Nemni, R; Previtali, S; Quattrini, A; Villa, E | 1 |
| Heimans, JJ; Hoekman, K; Postma, TJ; van Riel, JM; Vermorken, JB | 1 |
| Aravantinos, G; Dimopoulos, MA; Georgoulias, V; Gika, D; Karpathios, S; Moulopoulos, LA; Papadimitriou, CA; Stamatelopoulos, S | 1 |
| Gallagher, CJ; Mason, M; McClaren, BR; Mulatero, C; Oliver, RT | 1 |
| Eisenberger, MA; Laufer, M; Schoenberg, MP | 1 |
| Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A | 1 |
| Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT | 1 |
| Fleming, GF; Langhauser, C; Rotmensch, J; Waggoner, SE | 1 |
| Assouline, D; Bennouna, J; Douillard, JY; Grau, B; Haller, AM; Lerouge, D; Monnier, A; Rivière, A; Sun, XS | 1 |
| Antman, K; Bagiella, E; Balmaceda, C; Donovan, D; Frederick, D; Garrett, T; Hesdorffer, CS; Kaufman, E; Lange, D; Leuin, S; Nichols, G; Papadopoulos, K; Savage, D; Tiersten, A; Vahdat, L | 1 |
| Alvarnas, J; Chow, W; Doroshow, JH; Forman, SJ; Kogut, N; Leong, LA; Longmate, J; Margolin, KA; Morgan, RJ; Raschko, JW; Reardon, D; Schriber, J; Shibata, SI; Somlo, G; Synold, T; Tetef, ML; Yen, Y | 1 |
| Hiramatsu, H; Kikuchi, Y; Kita, T; Seto, H | 1 |
| Cheema, SS; Kilpatrick, TJ; Lopes, EC; Phan, S; Reardon, K | 1 |
| Antonuzzo, A; Crinó, L; Darwish, S; Galli, L; Marrocolo, F; Novello, S; Pozzi, E; Ricci, S; Scagliotti, GV; Selvaggi, G; Sorbolini, S; Tonato, M | 1 |
| Ishikawa, H; Kuzuya, K; Nakanishi, T; Nawa, A; Suzuki, Y | 1 |
| Bennett, GJ; Clark, US; Mannes, AJ; Polomano, RC | 1 |
| Chen, X; Dina, OA; Levine, JD; Reichling, D | 1 |
| Chacón, JI; de Castro, J; Dorta, J; Espinosa, E; Feliu, J; González Barón, M; Lizón, J; Martin, G; Rodríguez, A; Sánchez Heras, B; Torrego, JC | 1 |
| Beatson, C; Boyle, FM; Grant, SL; Kurek, JB; Monk, R | 1 |
| Nishiwaki, Y; Saijo, N; Sakai, H; Tamura, T; Watanabe, K; Yokoyama, A; Yoneda, S | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
| Clark, B; Ettinger, DS; Forastiere, AA; Gilbert, MR; Grochow, LB; Lubejko, BG; McGuire, WP; Noe, DA; Rowinsky, EK; Sartorius, SE | 1 |
| Buzdar, AU; Forman, AD; Frye, DK; Holmes, FA; Hortobagyi, GN; Newton, LK; Raber, MN; Theriault, RL; Walters, RS | 1 |
| Burke, PJ; Donehower, RC; Ettinger, DS; Karp, JE; Rowinsky, EK; Tucker, RW | 1 |
| Armstrong, DK; Donehower, RC; Ettinger, DS; Grumbine, FC; McGuire, WP; Rosenshein, NB; Rowinsky, EK | 1 |
| Raine, CS; Röytta, M | 1 |
38 review(s) available for paclitaxel and Peripheral Nervous System Diseases
| Article | Year |
|---|---|
Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Topics: Antineoplastic Agents; Duloxetine Hydrochloride; Humans; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Pregabalin; Randomized Controlled Trials as Topic | 2022 |
Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Topics: Breast Neoplasms; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Female; Genetic Markers; Humans; Liver-Specific Organic Anion Transporter 1; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Polymorphism, Single Nucleotide; Taxoids | 2022 |
Towards a mechanistic understanding of axon transport and endocytic changes underlying paclitaxel-induced peripheral neuropathy.
Topics: Axonal Transport; Axons; Humans; Microtubules; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems.
Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Mice; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rodentia | 2020 |
Recent advances in understanding chemotherapy-induced peripheral neuropathy.
Topics: Antineoplastic Agents; Humans; Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Quality of Life | 2020 |
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
Topics: Adult; Aged; Cells, Cultured; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Neurites; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sphingosine-1-Phosphate Receptors; Tubulin Modulators; Young Adult | 2020 |
Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis.
Topics: Antineoplastic Agents, Phytogenic; Humans; Paclitaxel; Peripheral Nervous System Diseases; Polyglutamic Acid; Solvents | 2021 |
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
Topics: Animals; Antineoplastic Agents; Biomarkers; Docetaxel; Dose-Response Relationship, Drug; Humans; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Precision Medicine | 2021 |
Neuro-immune interactions in paclitaxel-induced peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Neuroimmunomodulation; Paclitaxel; Peripheral Nervous System Diseases | 2021 |
Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Disease Models, Animal; Humans; Oxidative Stress; Paclitaxel; Peripheral Nervous System Diseases; Pre-Exposure Prophylaxis; Translational Research, Biomedical | 2021 |
Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Humans; Incidence; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Solvents | 2019 |
Defining risks of taxane neuropathy: insights from randomized clinical trials.
Topics: Axons; Bridged-Ring Compounds; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Nanoparticles; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Taxoids | 2013 |
[Peripheral neuropathy induced by anticancer drugs].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cold Temperature; Drugs, Chinese Herbal; Humans; Hyperalgesia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sensation Disorders; Vincristine; Vitamin B 12 | 2013 |
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2014 |
Rodent models of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Mice; Nerve Degeneration; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Rats; Vincristine | 2014 |
Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.
Topics: Albumins; Antineoplastic Agents; Humans; Incidence; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Risk; Severity of Illness Index; Taxoids | 2017 |
Chemotherapy-induced peripheral neuropathy: Current status and progress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Models, Neurological; Neural Stem Cells; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2016 |
Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance).
Topics: Alleles; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Male; Multidrug Resistance-Associated Protein 2; Neoplasms; Odds Ratio; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide | 2016 |
[Role of Transient Receptor Potential Channels in Paclitaxel- and Oxaliplatin-induced Peripheral Neuropathy].
Topics: Acute Disease; Animals; Antineoplastic Agents; Calcium Channels; Ganglia, Spinal; Gene Expression; Humans; Hyperalgesia; Molecular Targeted Therapy; Nerve Tissue Proteins; Organoplatinum Compounds; Oxaliplatin; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Peripheral Nervous System Diseases; Rats; Spinal Cord Dorsal Horn; Substance P; Transient Receptor Potential Channels; TRPA1 Cation Channel; TRPV Cation Channels; Up-Regulation | 2016 |
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic Agents; Baclofen; Calcium; Glutamine; Humans; Infusions, Intravenous; Ketamine; Magnesium; Naphthalenes; Nootropic Agents; Paclitaxel; Peripheral Nervous System Diseases; Pyridines; Randomized Controlled Trials as Topic; Vitamin E | 2008 |
Recent advances in drug-induced neuropathies.
Topics: Animals; Antineoplastic Agents; Cisplatin; Humans; Immunosuppressive Agents; Paclitaxel; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Suramin; Vincristine | 2002 |
Managing taxane toxicities.
Topics: Antineoplastic Agents, Phytogenic; Arthralgia; Bridged-Ring Compounds; Docetaxel; Drug Hypersensitivity; Humans; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thrombocytopenia | 2003 |
[Neurotoxic effects of medications: an update].
Topics: Anti-Retroviral Agents; Antineoplastic Agents; Carboplatin; Cisplatin; Colchicine; Docetaxel; Humans; Interferon-alpha; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thalidomide | 2004 |
Neuropathic pain associated with non-surgical treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Models, Animal; Female; Humans; Neuralgia; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases; Radiation Injuries; Radiotherapy; Rats | 2005 |
Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.
Topics: Antineoplastic Agents, Phytogenic; Humans; Paclitaxel; Peripheral Nervous System Diseases; Pharmaceutical Vehicles; Polyethylene Glycols; Prognosis; Risk Factors | 2006 |
Advances in understanding drug-induced neuropathies.
Topics: Antineoplastic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Thalidomide | 2006 |
Peripheral neuropathy induced by microtubule-stabilizing agents.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Epothilones; Humans; Microtubules; Neuroprotective Agents; Paclitaxel; Pain Management; Peripheral Nervous System Diseases; Risk Factors; Tubulin Modulators | 2006 |
[Adverse effects of therapeutic drugs on peripheral nervous system].
Topics: Anti-HIV Agents; Anticonvulsants; Antineoplastic Agents; Antitubercular Agents; Cisplatin; Dose-Response Relationship, Drug; Early Diagnosis; Humans; Immunosuppressive Agents; Paclitaxel; Peripheral Nervous System Diseases; Phenytoin; Tacrolimus; Thalidomide; Vincristine | 2007 |
[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
Topics: Animals; Bone Marrow; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Tubulin Modulators | 2008 |
[Neuropathy induced by antineoplastic drugs].
Topics: Antineoplastic Agents; Cisplatin; Humans; Interferons; Paclitaxel; Peripheral Nervous System Diseases; Vincristine | 2008 |
Paclitaxel (taxol)
Topics: Arrhythmias, Cardiac; Breast Neoplasms; Drug Hypersensitivity; Female; Humans; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1995 |
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Cell Cycle; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Hypersensitivity; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Humans; Mice; Microtubules; Neoplasms; Neoplasms, Experimental; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Polyethylene Glycols; Taxoids; Tubulin | 1994 |
Neurotoxicity of Taxol.
Topics: Humans; Motor Neuron Disease; Nervous System; Neurons, Afferent; Paclitaxel; Peripheral Nervous System Diseases | 1993 |
Patient care issues: the management of paclitaxel-related toxicities.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Gastrointestinal Diseases; Humans; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
Clinical toxicities encountered with paclitaxel (Taxol).
Topics: Alopecia; Arrhythmias, Cardiac; Brain Diseases; Clinical Trials as Topic; Drug Administration Schedule; Drug Hypersensitivity; Gastrointestinal Diseases; Humans; Immunoglobulin E; Models, Biological; Muscular Diseases; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Risk Factors | 1993 |
Current dosage and schedule issues in the development of paclitaxel (Taxol).
Topics: Animals; Bone Marrow Diseases; Clinical Trials as Topic; Dogs; Dose-Response Relationship, Drug; Drug Evaluation; Drug Evaluation, Preclinical; Drug Hypersensitivity; Humans; Mice; Microtubules; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Rats; Time Factors | 1993 |
Neurotrophic factors and diabetic peripheral neuropathy.
Topics: Animals; Diabetic Neuropathies; Disease Models, Animal; Humans; Nerve Compression Syndromes; Nerve Growth Factors; Paclitaxel; Peripheral Nervous System Diseases; Vinblastine | 1999 |
[Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] .
Topics: Anti-HIV Agents; Antineoplastic Agents; Cyclosporine; Depsipeptides; Docetaxel; Doxorubicin; Humans; Neoplasms; Neuromuscular Diseases; Oligopeptides; Organoplatinum Compounds; Paclitaxel; Peripheral Nervous System Diseases; Procarbazine; Reverse Transcriptase Inhibitors; Suramin; Taxoids; Vinca Alkaloids | 2000 |
142 trial(s) available for paclitaxel and Peripheral Nervous System Diseases
| Article | Year |
|---|---|
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
Topics: Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Functional Status; Gastrointestinal Diseases; Humans; Neoplasm Staging; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Quality of Life | 2022 |
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Phthalazines; Piperazines; Quinazolines | 2022 |
Impact of Cold Therapy on Paclitaxel-Induced Peripheral Neuropathy and Quality of Life in Patients With Breast Cancer.
Topics: Breast Neoplasms; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2022 |
Efficacy of Siriraj, in-house-developed, frozen gloves for cold therapy reduction of chemotherapy-induced peripheral neuropathy in gynecological cancer patients: randomized controlled trial.
Topics: Adult; Antineoplastic Agents; Cryotherapy; Humans; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE.
Topics: Acetylcholinesterase; Aminoquinolines; Breast Neoplasms; Cholinesterase Inhibitors; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Thioctic Acid | 2022 |
Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Doxorubicin; Female; Humans; Neurotensin; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Thioctic Acid; Tumor Necrosis Factor-alpha | 2022 |
Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial.
Topics: Albumins; Breast Neoplasms; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 2022 |
Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Polyethylene Glycols; Polymers | 2022 |
Efficacy of Duloxetine on electrodiagnostic findings of Paclitaxel-induced peripheral neuropathy, does it have a prophylactic effect? A randomized clinical trial.
Topics: Breast Neoplasms; Duloxetine Hydrochloride; Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Randomized double-blind, placebo-controlled study of oral gabapentin for prevention of neuropathy in patients receiving paclitaxel.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Gabapentin; Humans; India; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ASSESSED BY ELECTRONEUROMYOGRAPHY OF SUPERFICIAL PERONEAL AND SURAL NERVES.
Topics: Acetylcholinesterase; Breast Neoplasms; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Sural Nerve; Thioctic Acid | 2022 |
Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies | 2023 |
Persistent weekly paclitaxel-induced peripheral neuropathy in early breast cancer patients enrolled in a randomized trial of cryotherapy.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cross-Sectional Studies; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Effect of cilostazol on preventing paclitaxel-induced neuropathy in patients with breast cancer: A randomized controlled trial.
Topics: Breast Neoplasms; Cilostazol; Female; Humans; Nerve Growth Factor; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2023 |
A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Gloves, Surgical; Humans; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Taxoids | 2023 |
A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2.
Topics: Acute Pain; Breast Neoplasms; Double-Blind Method; Fatty Acids, Omega-3; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects | 2023 |
Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial.
Topics: Antineoplastic Agents; Female; Genital Neoplasms, Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Mice; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Risk Factors; Vitamin D; Vitamin D Deficiency | 2023 |
Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cryotherapy; Female; Foot; Hand; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Prospective Studies | 2019 |
Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Exercise Therapy; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Quality of Life; Survival Rate | 2019 |
[Effects of cryotherapy on chemotherapy-induced peripheral neuropathy: self-controlled clinical trial].
Topics: Antineoplastic Agents; Breast Neoplasms; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2019 |
Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Compression Bandages; Cryotherapy; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Treatment Outcome | 2020 |
Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
Topics: Aged; Breast Neoplasms; Cryotherapy; Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Surveys and Questionnaires | 2020 |
Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Topics: Acetylcysteine; Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lipid Peroxidation; Malondialdehyde; Middle Aged; Nerve Growth Factor; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life | 2020 |
Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.
Topics: Adult; Aged; Breast Neoplasms; Compression Bandages; Double-Blind Method; Female; Gloves, Surgical; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Young Adult | 2021 |
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind
Topics: Administration, Intravenous; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pharmaceutical Preparations; Platinum; Quality of Life; Randomized Controlled Trials as Topic; Selenium | 2021 |
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Integrin alphaVbeta3; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Receptors, Vitronectin; Snake Venoms; Treatment Outcome | 2017 |
A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I.
Topics: Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Middle Aged; Minocycline; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects | 2017 |
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Epothilones; Female; Humans; Models, Biological; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases | 2017 |
Cold therapy to prevent paclitaxel-induced peripheral neuropathy.
Topics: Adult; Aged; Breast Neoplasms; Cryotherapy; Female; Humans; Hypothermia, Induced; Middle Aged; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Surveys and Questionnaires; Treatment Outcome | 2018 |
Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Exercise; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Sensorimotor Cortex; Survivors; Young Adult | 2018 |
A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Topics: Acupuncture Therapy; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Contusions; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Peripheral Nervous System Diseases; Severity of Illness Index; Treatment Outcome | 2018 |
Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Double-Blind Method; Female; Gabapentin; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Placebos | 2019 |
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genotype; Humans; Lymph Nodes; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Poisson Distribution; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Recurrence; Risk; Trastuzumab; Treatment Outcome | 2019 |
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Can
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Receptor, ErbB-2; Republic of Korea; Surveys and Questionnaires | 2019 |
A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Treatment Outcome | 2019 |
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
Topics: Antineoplastic Agents, Phytogenic; Axons; Breast Neoplasms; Female; Humans; Multifactorial Inheritance; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Sensory Receptor Cells | 2014 |
North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Female; Glutathione; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Placebos | 2014 |
Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Taxoids | 2015 |
Pharmacological Modulation of the Mitochondrial Electron Transport Chain in Paclitaxel-Induced Painful Peripheral Neuropathy.
Topics: Animals; Antimycin A; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Electron Transport; Electron Transport Chain Complex Proteins; Enzyme Inhibitors; Hyperalgesia; Male; Motor Activity; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Psychomotor Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Single-Blind Method; Time Factors | 2015 |
Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Topics: Acute Pain; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hypesthesia; Male; Middle Aged; Neoplasms; Paclitaxel; Paresthesia; Peripheral Nervous System Diseases; Pilot Projects; Placebos; Pregabalin; Quality of Life; Surveys and Questionnaires | 2016 |
Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy.
Topics: Adolescent; Adult; Breast Neoplasms; Cell Line, Tumor; Female; HEK293 Cells; Humans; Middle Aged; Neurotoxins; Paclitaxel; Peripheral Nervous System Diseases; Sphingolipids | 2015 |
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 2016 |
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.
Topics: Antineoplastic Agents, Phytogenic; Black or African American; Breast Neoplasms; Chemotherapy, Adjuvant; Exome Sequencing; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Paclitaxel; Peripheral Nervous System Diseases; Phenotype; Polymorphism, Single Nucleotide; Protein Tyrosine Phosphatases, Non-Receptor; Risk Factors | 2016 |
Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytochrome P-450 CYP2C8; Female; Gene Frequency; Genotype; Humans; Microfilament Proteins; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide | 2016 |
A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome.
Topics: Acute Pain; Administration, Oral; Antineoplastic Agents, Phytogenic; Auranofin; Double-Blind Method; Female; Humans; Isoenzymes; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Protein Kinase C; Protein Kinase Inhibitors; Syndrome | 2017 |
Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Mice; Middle Aged; Models, Biological; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies | 2016 |
Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Female; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Humans; Male; Middle Aged; Neoplasms; Neurofeedback; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Platinum Compounds; Survivors; Taxoids; Time Factors; Treatment Outcome; Waiting Lists | 2017 |
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infections; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Salvage Therapy; Stomach Neoplasms | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms | 2009 |
A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Treatment Outcome | 2009 |
Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Double-Blind Method; Female; Glutamic Acid; Humans; Middle Aged; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 2009 |
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pemetrexed; Peripheral Nervous System Diseases; Survival Analysis | 2010 |
Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0
Topics: Aged; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Pyrimidines; Stomach Neoplasms; Tokyo; Treatment Outcome | 2009 |
Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Thyroid Neoplasms; Time Factors; Tumor Burden | 2010 |
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Polyethylene Glycols; Recombinant Proteins | 2010 |
[Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs].
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Aged; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases | 2010 |
Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Self Report | 2010 |
Fractionated administration of carboplatin/paclitaxel reduces neurotoxicity in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis | 2011 |
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Granulosa Cell Tumor; Humans; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Peripheral Nervous System Diseases; Salvage Therapy; Tamoxifen; Thrombocytopenia; Treatment Outcome | 2011 |
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Recurrence | 2011 |
Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Paresthesia; Peripheral Nervous System Diseases; Quality of Life; Surveys and Questionnaires; Taxoids | 2012 |
Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Sarcoma, Endometrial Stromal; Uterine Neoplasms | 2012 |
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Genetic Loci; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Incidence; Microfilament Proteins; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Receptor, EphA5; Sensory Receptor Cells | 2012 |
Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Middle Aged; Neural Conduction; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 2012 |
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Palliative Care; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2002 |
Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate; Treatment Outcome | 2002 |
Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Mesna; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Pilot Projects; Prognosis; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neurologic Examination; Paclitaxel; Peripheral Nervous System Diseases; Radiation-Protective Agents; Treatment Outcome | 2003 |
Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Psychometrics; Reproducibility of Results | 2004 |
A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carboplatin; Carcinoma; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hyperglycemia; Life Tables; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2004 |
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Confidence Intervals; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Proportional Hazards Models; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
Topics: Administration, Oral; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Testicular Neoplasms; Uterine Cervical Neoplasms; Vitamin E | 2005 |
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors.
Topics: Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Polyglutamic Acid; Taxoids; Thrombocytopenia; Treatment Failure | 2005 |
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Interleukin-6; Leukemia Inhibitory Factor; Lipase; Male; Middle Aged; Neoplasms; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Placebos; Prospective Studies; Proteins | 2005 |
Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.
Topics: Action Potentials; Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Electrophysiology; Glutamine; Granulocyte Colony-Stimulating Factor; Humans; Melphalan; Neural Conduction; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Stem Cell Transplantation; Thiotepa | 2005 |
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Female; Humans; Infusion Pumps; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Time Factors; Treatment Outcome | 2005 |
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Severity of Illness Index; Time Factors; Topotecan | 2006 |
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2007 |
Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation.
Topics: Administration, Oral; Antineoplastic Agents; Dietary Supplements; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome; Vitamin E | 2006 |
Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Time Factors; Treatment Outcome | 2007 |
Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings.
Topics: Action Potentials; Adult; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Electric Stimulation; Electrophysiology; Female; Humans; Middle Aged; Neural Conduction; Neurologic Examination; Paclitaxel; Peripheral Nervous System Diseases; Reaction Time; Severity of Illness Index | 2008 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate | 2008 |
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2008 |
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Female; Gastrointestinal Diseases; Genes, erbB-2; Half-Life; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Trastuzumab | 2008 |
A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1995 |
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Topics: Aged; Bone Marrow Diseases; Drug Administration Schedule; Drug Hypersensitivity; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Musculoskeletal Diseases; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Topics: Drug Hypersensitivity; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Time Factors | 1994 |
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 1995 |
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cohort Studies; Disease Progression; Drug Resistance; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Middle Aged; Netherlands; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Thrombocytopenia | 1995 |
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Survival Rate; Thrombocytopenia | 1995 |
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Doxorubicin; Drug Administration Schedule; Female; Heart; Heart Failure; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction | 1995 |
Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cross-Over Studies; Disease Progression; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Remission Induction | 1995 |
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.
Topics: Adult; Carcinoma; Cisplatin; Drug Synergism; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases | 1995 |
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alopecia; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Remission Induction | 1995 |
[A phase II study of BMS-181339 in patients with ovarian cancer. BMS-181339 Ovarian Cancer Study Group].
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Female; Fever; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1994 |
Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Female; Histamine Antagonists; Humans; Hypotension; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Premedication | 1995 |
Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Remission Induction | 1995 |
Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axons; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction | 1995 |
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Topics: Adult; Aged; Agranulocytosis; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Thrombocytopenia | 1995 |
[Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Japan; Leukopenia; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Thrombocytopenia | 1996 |
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Incidence; Infusions, Intravenous; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Severity of Illness Index; Treatment Outcome | 1996 |
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Muscular Diseases; Neutropenia; Paclitaxel; Pain; Peripheral Nervous System Diseases; Remission Induction; Stroke Volume; Ventricular Function, Left | 1996 |
A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Drug Tolerance; Epirubicin; Feasibility Studies; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins; Remission Induction; Stroke Volume; Ventricular Function, Left | 1996 |
Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Tolerance; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 1996 |
Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 1996 |
Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1996 |
Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Tolerance; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 1996 |
Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer.
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Eruptions; Drug Tolerance; Humans; Lung Diseases; Lung Neoplasms; Muscular Diseases; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1996 |
Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate; Thrombocytopenia; Treatment Outcome | 1996 |
One-hour paclitaxel in the treatment of non-small cell lung cancer.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Tolerance; Esophagitis; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate | 1996 |
Phase I/II study of paclitaxel and radiotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Tolerance; Esophagitis; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage | 1996 |
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Thrombocytopenia | 1997 |
Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Cisplatin; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins | 1997 |
Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Failure | 1997 |
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Risk Factors; Sensory Thresholds | 1997 |
Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Thrombocytopenia | 1997 |
Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Electrophysiology; Female; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Vibration | 1997 |
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; France; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Arthralgia; Carboplatin; Dose-Response Relationship, Drug; Female; Germany; Humans; Infusions, Intravenous; Middle Aged; Neoplasm, Residual; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pain; Patient Selection; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Remission Induction; Retrospective Studies; Single-Blind Method; Survival Rate; Thrombocytopenia; Vomiting | 1997 |
Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Topics: Adult; Aged; Ambulatory Care; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Argentina; Biomarkers, Tumor; CA-125 Antigen; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Remission Induction; Survival Rate; Thrombocytopenia; Vomiting | 1997 |
Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Incidence; Infusions, Intravenous; Laparotomy; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Reoperation; Spain; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel.
Topics: Adult; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germinoma; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 1998 |
Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neurologic Examination; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1999 |
Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study.
Topics: Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2000 |
Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Constipation; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Middle Aged; Mouth Mucosa; Nausea; Paclitaxel; Peripheral Nervous System Diseases; Stomatitis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vomiting | 2000 |
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Regression Analysis; Thiotepa; Time Factors | 2001 |
Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Platinum Compounds; Vinblastine; Vinorelbine | 2001 |
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Topics: Activities of Daily Living; Administration, Oral; Antineoplastic Agents, Phytogenic; Female; Glutamine; Humans; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases | 2001 |
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 2001 |
Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis | 2001 |
3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Predictive Value of Tests; Treatment Outcome | 2001 |
Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome; Vinblastine | 2001 |
A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Hypotension; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Microtubules; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1991 |
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Agranulocytosis; Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Evaluation; Female; Heart Diseases; Humans; Methotrexate; Middle Aged; Muscular Diseases; Paclitaxel; Pain; Peripheral Nervous System Diseases; Remission Induction; Soft Tissue Neoplasms; Thrombocytopenia | 1991 |
376 other study(ies) available for paclitaxel and Peripheral Nervous System Diseases
| Article | Year |
|---|---|
Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ganglia, Spinal; Mice; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
The protective effects of hesperidin against paclitaxel-induced peripheral neuropathy in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Hesperidin; Male; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2021 |
Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.
Topics: Analgesics; Animals; Antineoplastic Agents; Corticosterone; Duloxetine Hydrochloride; Female; Male; Oxaliplatin; Paclitaxel; Pain Management; Pain Threshold; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2022 |
Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy.
Topics: Adenosine Triphosphate; Animals; HMGB1 Protein; Macrophages; Male; Mice; Mice, Inbred Strains; Neurons; Paclitaxel; Peripheral Nervous System Diseases; RAW 264.7 Cells; Receptor Cross-Talk; Receptors, Purinergic P2X4; Receptors, Purinergic P2X7 | 2022 |
Sarm1 activation produces cADPR to increase intra-axonal Ca++ and promote axon degeneration in PIPN.
Topics: Animals; Armadillo Domain Proteins; Axons; Calcium; Calcium Channels; Cyclic ADP-Ribose; Cytoskeletal Proteins; Female; HEK293 Cells; Humans; Mice, Inbred C57BL; Nerve Degeneration; Paclitaxel; Peripheral Nervous System Diseases; Rats, Sprague-Dawley | 2022 |
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy-Related Cognitive Impairment; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fatigue; Female; Humans; Long Term Adverse Effects; Longitudinal Studies; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Sleep Initiation and Maintenance Disorders | 2022 |
Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cancer Survivors; Drug Therapy; Duloxetine Hydrochloride; Female; Genital Neoplasms, Female; Humans; Japan; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Risk Factors | 2021 |
The impact of SBF2 on taxane-induced peripheral neuropathy.
Topics: Black or African American; Cell Survival; Disease Progression; Female; Gene Knockdown Techniques; Humans; Induced Pluripotent Stem Cells; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Protein Tyrosine Phosphatases, Non-Receptor; Quality of Life; Sensory Receptor Cells; Sequence Analysis, RNA; Single-Cell Analysis; White People | 2022 |
Dual PI3Kδ/γ Inhibitor Duvelisib Prevents Development of Neuropathic Pain in Model of Paclitaxel-Induced Peripheral Neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Female; Hyperalgesia; Isoquinolines; Male; Mice; Neuralgia; Paclitaxel; Pain; Peripheral Nervous System Diseases; Phosphatidylinositol 3-Kinases; Purines; Rats | 2022 |
Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Immunotherapy; Muscles; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Paclitaxel in vitro reversibly sensitizes the excitability of IB4(-) and IB4(+) sensory neurons from male and female rats.
Topics: Animals; Antineoplastic Agents; Female; Ganglia, Spinal; Humans; Male; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sensory Receptor Cells | 2022 |
Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy.
Topics: Antineoplastic Agents; Biomarkers; Cohort Studies; Humans; Neurofilament Proteins; Paclitaxel; Peripheral Nervous System Diseases; Polyneuropathies | 2022 |
Participation of transient receptor potential vanilloid 1 in the analgesic effect of duloxetine for paclitaxel induced peripheral neuropathic pain.
Topics: Analgesics; Animals; Antineoplastic Agents; Calcitonin Gene-Related Peptide; Duloxetine Hydrochloride; Ganglia, Spinal; Hyperalgesia; Neuralgia; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats; Spinal Cord Dorsal Horn; Substance P; TRPV Cation Channels; Tumor Necrosis Factor-alpha | 2022 |
Methods and protocols for chemotherapy-induced peripheral neuropathy (CIPN) mouse models using paclitaxel.
Topics: Animals; Antineoplastic Agents; Humans; Hyperalgesia; Mice; Mice, Inbred C57BL; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients.
Topics: Adult; Biomarkers; Breast Neoplasms; Female; Humans; Intermediate Filaments; Middle Aged; Neurofilament Proteins; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Ovariectomy increases paclitaxel-induced mechanical hypersensitivity and reduces anti-inflammatory CD4+ T cells in the dorsal root ganglion of female mice.
Topics: Animals; Anti-Inflammatory Agents; CD4-Positive T-Lymphocytes; Female; Ganglia, Spinal; Humans; Interleukin-10; Interleukin-4; Male; Mice; Ovariectomy; Paclitaxel; Peripheral Nervous System Diseases; Rats | 2022 |
Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer.
Topics: Albumins; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Quality of Life; Risk Factors | 2022 |
Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions.
Topics: Animals; Antineoplastic Agents; Hyperalgesia; Mice; Molecular Docking Simulation; Paclitaxel; Peripheral Nervous System Diseases; Rats; Receptor, Anaphylatoxin C5a | 2022 |
Analgesic and preventive effects of donepezil in animal models of chemotherapy-induced peripheral neuropathy: Involvement of spinal muscarinic acetylcholine M2 receptors.
Topics: Acetylcholine; Analgesics; Animals; Antineoplastic Agents; Cholinesterase Inhibitors; Donepezil; Leukemia, Myeloid, Acute; Models, Animal; Paclitaxel; Peripheral Nervous System Diseases; Rats; Receptor, Muscarinic M2; Receptors, Muscarinic | 2022 |
Taxane-induced neuropathy: How serious is this problem for patients with early breast cancer?
Topics: Breast Neoplasms; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Retrospective Studies; Taxoids | 2023 |
Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life | 2022 |
Shaoyao Gancao Decoction Ameliorates Paclitaxel-Induced Peripheral Neuropathy via Suppressing TRPV1 and TLR4 Signaling Expression in Rats.
Topics: Animals; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Hyperalgesia; Myeloid Differentiation Factor 88; Paclitaxel; Peripheral Nervous System Diseases; Rats; Toll-Like Receptor 4; TRPV Cation Channels | 2022 |
Case Report: Chemoradiation with Paclitaxel and Carboplatin Unveiling Leprosy Type 1 Downgrading Reaction.
Topics: Carboplatin; Humans; Hypersensitivity; Leprosy; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cannabidiol; Humans; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Effect of cryotherapy on paclitaxel-induced peripheral neuropathy of the hand in female breast cancer patients: A prospective self-controlled study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 2023 |
Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Stomach Neoplasms | 2022 |
Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity.
Topics: Biomarkers; Breast Neoplasms; Female; Humans; Intermediate Filaments; Neurofilament Proteins; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin.
Topics: Antineoplastic Agents; Biomarkers; Carboplatin; Glial Fibrillary Acidic Protein; Humans; Intermediate Filaments; Paclitaxel; Peripheral Nervous System Diseases; Ubiquitin Thiolesterase | 2022 |
Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Taxoids | 2022 |
[Possibility of Prolonging Treatment by Preventing Paclitaxel-Induced Peripheral Neuropathy Using Compression Therapy].
Topics: Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study.
Topics: Computational Biology; Gene Ontology; Genome-Wide Association Study; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer.
Topics: Biomarkers; Carboplatin; Female; Humans; Induced Pluripotent Stem Cells; Intermediate Filaments; Neurofilament Proteins; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Retrospective Studies; Sensory Receptor Cells | 2023 |
Protective effect of a mitochondria-targeting peptide against paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Hyperalgesia; Mice; Mitochondria; Paclitaxel; Peptides; Peripheral Nervous System Diseases; Quality of Life | 2023 |
Palmitoylethanolamide Mitigates Paclitaxel Toxicity in Primary Dorsal Root Ganglion Neurons.
Topics: Animals; Antineoplastic Agents, Phytogenic; Ganglia, Spinal; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Sensory Receptor Cells | 2022 |
Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study.
Topics: Breast Neoplasms; Chlorides; East Asian People; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2023 |
Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Humans; Lung Neoplasms; Male; Mammals; Micelles; Nanoparticles; Paclitaxel; Peripheral Nervous System Diseases; Polymers; Rats; Rats, Sprague-Dawley | 2023 |
Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy.
Topics: Animals; Axons; Nerve Tissue; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Rats | 2023 |
Khellin as a selective monoamine oxidase B inhibitor ameliorated paclitaxel-induced peripheral neuropathy in mice.
Topics: Animals; Hyperalgesia; Khellin; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
AIBP regulates TRPV1 activation in chemotherapy-induced peripheral neuropathy by controlling lipid raft dynamics and proximity to TLR4 in dorsal root ganglion neurons.
Topics: Animals; Antineoplastic Agents; Carrier Proteins; Cholesterol; Ganglia, Spinal; Membrane Microdomains; Mice; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Toll-Like Receptor 4; TRPV Cation Channels | 2023 |
Comparative Transcriptome of Dorsal Root Ganglia Reveals Distinct Etiologies of Paclitaxel- and Oxaliplatin-induced Peripheral Neuropathy in Rats.
Topics: Animals; Antineoplastic Agents; Ganglia, Spinal; Hyperalgesia; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Rats; Transcriptome | 2023 |
Trimetazidine alleviates paclitaxel-induced peripheral neuropathy through modulation of TLR4/p38/NF-κB and klotho protein expression.
Topics: Animals; Male; Mice; NF-kappa B; Paclitaxel; Peripheral Nervous System Diseases; Toll-Like Receptor 4; Trimetazidine | 2023 |
Hyperbaric Oxygen Therapy Alleviates Paclitaxel-Induced Peripheral Neuropathy Involving Suppressing TLR4-MyD88-NF-κB Signaling Pathway.
Topics: Animals; Antineoplastic Agents; Hyperalgesia; Hyperbaric Oxygenation; Lipopolysaccharides; Myeloid Differentiation Factor 88; NF-kappa B; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptor 4 | 2023 |
An efficient cellular image-based platform for high-content screening of neuroprotective agents against chemotherapy-induced neuropathy.
Topics: Antineoplastic Agents; Ganglia, Spinal; Humans; Neurons; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
An evaluation of the effect of lithium on taxane-induced neuropathy.
Topics: Antineoplastic Agents; Humans; Lithium; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids | 2023 |
Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103.
Topics: Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Humans; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2023 |
Fluocinolone Acetonide Enhances Anterograde Mitochondria Trafficking and Promotes Neuroprotection against Paclitaxel-Induced Peripheral Neuropathy.
Topics: Fluocinolone Acetonide; Humans; Mitochondria; Neuroprotection; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Glycyrrhizic Acid Prevents Paclitaxel-Induced Neuropathy via Inhibition of OATP-Mediated Neuronal Uptake.
Topics: Glycyrrhizic Acid; Humans; Membrane Transport Proteins; Neurons; Organic Anion Transporters; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Evaluation of neurotoxicity of anticancer drugs using nematode Caenorhabditis elegans as a model organism.
Topics: Animals; Antineoplastic Agents; Caenorhabditis elegans; Cisplatin; Humans; Neurotoxicity Syndromes; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Vincristine | 2023 |
Protease-Activated Receptor 2 (PAR2) Expressed in Sensory Neurons Contributes to Signs of Pain and Neuropathy in Paclitaxel Treated Mice.
Topics: Animals; Female; Ganglia, Spinal; Gliosis; Hyperalgesia; Male; Mice; Mice, Knockout; Paclitaxel; Pain; Peripheral Nervous System Diseases; Receptor, PAR-2; Sensory Receptor Cells | 2023 |
Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Receptors, G-Protein-Coupled; Taxoids | 2023 |
Schwann Cell-Derived Exosomes Ameliorate Paclitaxel-Induced Peripheral Neuropathy Through the miR-21-Mediated PTEN Signaling Pathway.
Topics: Animals; Exosomes; HeLa Cells; Humans; MicroRNAs; Paclitaxel; Peripheral Nervous System Diseases; PTEN Phosphohydrolase; Rats; Schwann Cells; Signal Transduction | 2023 |
Intrathecal rapamycin attenuates the mechanical hyperalgesia of paclitaxel-induced peripheral neuropathy in mice.
Topics: Animals; Antineoplastic Agents; Hyperalgesia; Mice; Paclitaxel; Peripheral Nervous System Diseases; Sirolimus | 2023 |
Thymoquinone Alleviates Paclitaxel-Induced Peripheral Neuropathy through Regulation of the TLR4-MyD88 Inflammatory Pathway.
Topics: Animals; Mice; Molecular Docking Simulation; Myeloid Differentiation Factor 88; Neuroprotective Agents; NF-kappa B; Paclitaxel; Peripheral Nervous System Diseases; Toll-Like Receptor 4 | 2023 |
Mitochondrial trafficking as a protective mechanism against chemotherapy drug-induced peripheral neuropathy: Identifying the key site of action.
Topics: Antineoplastic Agents; Cisplatin; Humans; Mitochondria; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Pharmaceutical Preparations | 2023 |
Renin-angiotensin-aldosterone system inhibitors are associated with improved paclitaxel-induced peripheral neuropathy in lung cancer: a study using administrative claims data.
Topics: Antihypertensive Agents; Cohort Studies; Humans; Hypertension; Lung Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Renin-Angiotensin System | 2023 |
Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cancer Survivors; Female; Humans; Inflammation; Paclitaxel; Peripheral Nervous System Diseases; Transcriptome | 2019 |
Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cross-Sectional Studies; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2019 |
Pharmacological interventions targeting Wnt/β-catenin signaling pathway attenuate paclitaxel-induced peripheral neuropathy.
Topics: Animals; Behavior, Animal; Depsipeptides; Gene Expression Regulation; Male; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Pyridines; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Wnt Signaling Pathway | 2019 |
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Topics: Administration, Intravenous; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Japan; Oxaliplatin; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires | 2019 |
A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Incidence; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Pilot Projects; Risk Assessment; Risk Factors; Skin; Young Adult | 2020 |
Electroacupuncture Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Rats via Suppressing TLR4 Signaling and TRPV1 Upregulation in Sensory Neurons.
Topics: Animals; Antineoplastic Agents, Phytogenic; Electroacupuncture; Gene Expression Regulation; Male; Myeloid Differentiation Factor 88; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Toll-Like Receptor 4; TRPV Cation Channels | 2019 |
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
Topics: Albumins; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Computer Simulation; Drug Administration Schedule; Drug Tapering; Epothilones; Female; Humans; Models, Biological; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Precision Medicine | 2020 |
Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy.
Topics: Adult; Aged; Cryotherapy; Docetaxel; Extremities; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Retrospective Studies; Treatment Outcome | 2020 |
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers; Breast Neoplasms; Female; Genetic Variation; Humans; Paclitaxel; Peripheral Nervous System Diseases; Receptors, Eph Family | 2020 |
Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Middle Aged; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Ramucirumab; Retrospective Studies; Stomach Neoplasms | 2020 |
Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Qualitative Research | 2020 |
Targeting interleukin-20 alleviates paclitaxel-induced peripheral neuropathy.
Topics: Animals; Ganglia, Spinal; Humans; Hyperalgesia; Interleukins; Mice; Paclitaxel; Peripheral Nervous System Diseases | 2020 |
Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
Topics: Adult; Antineoplastic Agents; Case-Control Studies; China; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Surveys and Questionnaires | 2020 |
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Prospective Studies; Retrospective Studies; Severity of Illness Index; Vitamin D Deficiency | 2020 |
Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Electronic Health Records; Female; Health Literacy; Humans; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Pilot Projects; Socioeconomic Factors; Trust | 2020 |
Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Progression-Free Survival; Prospective Studies; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.
Topics: Antineoplastic Agents, Phytogenic; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin; Verapamil | 2020 |
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Middle Aged; NAV1.7 Voltage-Gated Sodium Channel; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate | 2020 |
Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Axons; Biomarkers; Cisplatin; Disease Models, Animal; Female; Neurofilament Proteins; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases; Rats, Wistar; Severity of Illness Index; Up-Regulation | 2020 |
Involvement of the Sodium Channel Nav1.7 in Paclitaxel-induced Peripheral Neuropathy through ERK1/2 Signaling in Rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Male; MAP Kinase Signaling System; NAV1.7 Voltage-Gated Sodium Channel; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2020 |
Nicotinamide riboside relieves paclitaxel-induced peripheral neuropathy and enhances suppression of tumor growth in tumor-bearing rats.
Topics: Animals; Female; Neoplasms; Niacinamide; Paclitaxel; Peripheral Nervous System Diseases; Pyridinium Compounds; Rats | 2020 |
Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Testicular Neoplasms; Young Adult | 2021 |
A Chemotherapy-Induced Peripheral Neuropathy Model in Drosophila melanogaster.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Axons; Dendrites; Disease Models, Animal; Dissection; Drosophila melanogaster; Female; Genotype; Larva; Male; Microscopy, Fluorescence; Nerve Degeneration; Paclitaxel; Peripheral Nervous System Diseases | 2020 |
Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathy.
Topics: Amygdala; Animals; Antineoplastic Agents, Phytogenic; Avoidance Learning; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Male; Mice; Mice, Inbred C57BL; Nucleus Accumbens; Paclitaxel; Peripheral Nervous System Diseases; Receptors, Opioid, kappa | 2020 |
Chemotherapy-induced peripheral neuropathy in a dish: dorsal root ganglion cells treated in vitro with paclitaxel show biochemical and physiological responses parallel to that seen in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Ganglia, Spinal; Humans; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2021 |
Dysregulation of EAAT2 and VGLUT2 Spinal Glutamate Transports via Histone Deacetylase 2 (HDAC2) Contributes to Paclitaxel-induced Painful Neuropathy.
Topics: Animals; Excitatory Amino Acid Transporter 2; Glutamic Acid; Histone Deacetylase 2; Male; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Vesicular Glutamate Transport Protein 2 | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-Over Studies; Deoxycytidine; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Progression-Free Survival; Registries; Republic of Korea; Survival Rate; Treatment Outcome | 2020 |
PINK1 alleviates thermal hypersensitivity in a paclitaxel-induced Drosophila model of peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drosophila; Drosophila Proteins; Gene Expression; Gene Knockdown Techniques; Hyperalgesia; Hyperesthesia; Paclitaxel; Peripheral Nervous System Diseases; Protein Serine-Threonine Kinases; Sensory Receptor Cells | 2020 |
Encapsulating paclitaxel in polymeric nanomicelles increases antitumor activity and prevents peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Carriers; Female; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Paclitaxel; Peripheral Nervous System Diseases; Polymers; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Effects of paclitaxel on the viscoelastic properties of mouse sensory nerves.
Topics: Animals; Mice; Mice, Inbred C57BL; Microtubules; Paclitaxel; Peripheral Nervous System Diseases; Rats; Sciatic Nerve | 2021 |
Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Taxoids | 2020 |
Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel.
Topics: Antineoplastic Agents; Cell Line; Humans; Induced Pluripotent Stem Cells; Intravital Microscopy; Membrane Potential, Mitochondrial; Mitochondria; Optical Imaging; Paclitaxel; Peripheral Nervous System Diseases; Sensory Receptor Cells; Synaptic Potentials | 2021 |
Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Cations; Cell Proliferation; Drug Compounding; Female; Ganglia, Spinal; Humans; Lipids; Liposomes; Lung Neoplasms; Mice, Inbred C57BL; Neoplastic Stem Cells; Paclitaxel; Particle Size; Peripheral Nervous System Diseases; Polyethylene Glycols; Tumor Burden | 2021 |
Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medicare; Paclitaxel; Peripheral Nervous System Diseases; United States | 2021 |
Comparative Analysis of Chemotherapy-Induced Peripheral Neuropathy in Bioengineered Sensory Nerve Tissue Distinguishes Mechanistic Differences in Early-Stage Vincristine-, Cisplatin-, and Paclitaxel-Induced Nerve Damage.
Topics: Animals; Antineoplastic Agents; Cisplatin; Humans; Nerve Tissue; Paclitaxel; Peripheral Nervous System Diseases; Rats; Vincristine | 2021 |
Targeting Peroxisome Proliferator-Activated Receptor-α (PPAR- α) to reduce paclitaxel-induced peripheral neuropathy.
Topics: Animals; Female; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Peripheral Nervous System Diseases; PPAR alpha | 2021 |
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Biomarkers; Disease Models, Animal; Disease Susceptibility; Humans; Hyperalgesia; Immunoglobulins, Intravenous; Macrophages; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Rats; Treatment Outcome | 2021 |
Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response.
Topics: Breast Neoplasms; Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2021 |
Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Colorectal Neoplasms; Female; Hemoglobins; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Obesity; Overweight; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Risk Factors; Severity of Illness Index; Sex Factors; Young Adult | 2021 |
Transcriptome profiling of long noncoding RNAs and mRNAs in spinal cord of a rat model of paclitaxel-induced peripheral neuropathy identifies potential mechanisms mediating neuroinflammation and pain.
Topics: Animals; Antineoplastic Agents, Phytogenic; Gene Expression Profiling; Gene Regulatory Networks; Male; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; RNA, Long Noncoding; RNA, Messenger; Spinal Cord | 2021 |
Pronociceptive Roles of Schwann Cell-Derived Galectin-3 in Taxane-Induced Peripheral Neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Proteins; Cell Movement; Chemotaxis; Clodronic Acid; Disease Models, Animal; Docetaxel; Female; Galectins; Humans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Paclitaxel; Pain Perception; Peripheral Nervous System Diseases; Prospective Studies; Rats; Schwann Cells; Sciatic Nerve; Up-Regulation | 2021 |
N-acylethanolamine-hydrolysing acid amidase: A new potential target to treat paclitaxel-induced neuropathy.
Topics: Amidohydrolases; Animals; Ethanolamines; Mice; Paclitaxel; Peripheral Nervous System Diseases; PPAR alpha | 2021 |
Impact of drug formulations on kinetics and toxicity in a preclinical model of paclitaxel-induced neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chromatography, Liquid; Drug Compounding; Ganglia, Spinal; Kinetics; Mice; Mice, Inbred C57BL; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Tandem Mass Spectrometry | 2021 |
Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation.
Topics: Animals; Blood Proteins; Breast Neoplasms; Cell Dedifferentiation; Cell Line, Tumor; Cilostazol; Demyelinating Diseases; Female; Galectins; Ganglia, Spinal; Humans; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Schwann Cells; Sciatic Nerve | 2021 |
Behavior and electrophysiology studies of the peripheral neuropathy induced by individual and co-administration of paclitaxel and oxaliplatin in rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Behavior, Animal; Electrophysiology; Male; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar | 2021 |
Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study.
Topics: Age Factors; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cancer Survivors; Estrogens; Female; Humans; Mice; Mice, Inbred Strains; Middle Aged; Ovariectomy; Paclitaxel; Peripheral Nervous System Diseases; Postmenopause; Rats; Retrospective Studies; Risk Factors; Thrombomodulin | 2021 |
Integrins protect sensory neurons in models of paclitaxel-induced peripheral sensory neuropathy.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Drosophila melanogaster; Endosomes; Female; Ganglia, Spinal; Integrins; Male; Mice; Mice, Inbred C57BL; Nociceptors; Paclitaxel; Peripheral Nervous System Diseases | 2021 |
Neuroimmune Consequences of eIF4E Phosphorylation on Chemotherapy-Induced Peripheral Neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Eukaryotic Initiation Factor-4E; Female; Ganglia, Spinal; Lymphocyte Activation; Macrophage Activation; Male; Mice; Mice, Inbred C57BL; Neuroimmunomodulation; Nociceptors; Paclitaxel; Peripheral Nervous System Diseases; Phosphorylation; Protein Biosynthesis | 2021 |
Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Armadillo Domain Proteins; Axons; Cells, Cultured; Cytoskeletal Proteins; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Mice; Mice, Knockout; Paclitaxel; Peripheral Nervous System Diseases; Thiazoles | 2021 |
Simultaneous hyperbaric oxygen therapy during systemic chemotherapy reverses chemotherapy-induced peripheral neuropathy by inhibiting TLR4 and TRPV1 activation in the central and peripheral nervous system.
Topics: Animals; Antineoplastic Agents; Ganglia, Spinal; Humans; Hyperbaric Oxygenation; Paclitaxel; Peripheral Nervous System Diseases; Rats; Toll-Like Receptor 4; TRPV Cation Channels | 2021 |
Uncomfortably numb: how Nav1.7 mediates paclitaxel-induced peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2021 |
RIP3/MLKL pathway-regulated necroptosis: A new mechanism of paclitaxel-induced peripheral neuropathy.
Topics: Animals; Male; Necroptosis; Paclitaxel; Peripheral Nervous System Diseases; Protein Kinases; Rats; Rats, Sprague-Dawley; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction | 2021 |
Preventive effects of self-administered cryotherapy on paclitaxel-induced peripheral neuropathy in patients with early-stage breast cancer: a propensity score analysis.
Topics: Breast Neoplasms; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Propensity Score; Retrospective Studies | 2021 |
Effects of combined chemotherapy and anti-programmed cell death protein 1 treatment on peripheral neuropathy and neuroinflammation in mice.
Topics: Animals; Ganglia, Spinal; Humans; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Paclitaxel; Peripheral Nervous System Diseases; Programmed Cell Death 1 Receptor | 2022 |
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Pharmacological; Breast Neoplasms; Egypt; Female; Genotype; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prognosis | 2021 |
Ketogenic diet prevents paclitaxel-induced neuropathic nociception through activation of PPARγ signalling pathway and inhibition of neuroinflammation in rat dorsal root ganglion.
Topics: Animals; Antineoplastic Agents, Phytogenic; Diet, Ketogenic; Ganglia, Spinal; Nociception; Paclitaxel; Peripheral Nervous System Diseases; PPAR gamma; Prospective Studies; Rats; Rats, Sprague-Dawley | 2021 |
An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Body Surface Area; Canada; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lumbar Vertebrae; Male; Maximum Tolerated Dose; Middle Aged; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Predictive Value of Tests; Reference Values; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Eosinophils; Escape Reaction; Female; Hyperalgesia; Leukocyte Count; Locomotion; NAD; Neutrophils; Niacinamide; Nociception; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Pyridinium Compounds; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Time Factors | 2017 |
Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy.
Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Calcium; Cell Line, Tumor; Disease Models, Animal; Ganglia, Spinal; Humans; Macrophages; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Minoxidil; Neoplasms; Neurites; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Sciatic Nerve | 2017 |
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Topics: Adult; Aged; Aging; Antineoplastic Agents, Phytogenic; Asian People; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cytochrome P-450 CYP2C8; Female; Genotype; Humans; Incidence; Middle Aged; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies; Sensory Receptor Cells; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2017 |
Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C8; Female; Humans; Male; Middle Aged; Odds Ratio; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine | 2017 |
Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy.
Topics: Action Potentials; Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Armadillo Domain Proteins; Cytoskeletal Proteins; Diet, High-Fat; Disease Models, Animal; Hyperalgesia; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neural Conduction; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Reaction Time; Sural Nerve | 2017 |
Paclitaxel-induced painful neuropathy is associated with changes in mitochondrial bioenergetics, glycolysis, and an energy deficit in dorsal root ganglia neurons.
Topics: Animals; Antineoplastic Agents, Phytogenic; Energy Metabolism; Ganglia, Spinal; Glycolysis; Male; Mitochondria; Neurons; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats, Sprague-Dawley | 2017 |
Involvement of Charcot-Marie-Tooth disease gene mitofusin 2 expression in paclitaxel-induced mechanical allodynia in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Charcot-Marie-Tooth Disease; Disease Models, Animal; GTP Phosphohydrolases; Hyperalgesia; Male; Membrane Proteins; Mitochondrial Proteins; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2017 |
Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Physicians | 2017 |
Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Retrospective Studies; Survival Rate | 2017 |
Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Cannabinoid Receptor Modulators; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Indoles; Male; Neuralgia; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Piperidines; Polycyclic Sesquiterpenes; Pyrazoles; Random Allocation; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Sesquiterpenes; Spinal Cord | 2017 |
Long-term peripheral neuropathy symptoms in breast cancer survivors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cancer Survivors; Cross-Sectional Studies; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Prevalence; Retrospective Studies; Taxoids | 2017 |
The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Treatment Failure | 2017 |
Nicotine Prevents and Reverses Paclitaxel-Induced Mechanical Allodynia in a Mouse Model of CIPN.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Hyperalgesia; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nicotine; Paclitaxel; Peripheral Nervous System Diseases; Receptors, Cholinergic; Taxoids | 2018 |
Relevance of the CYP3A4*20 variant as a predictor of paclitaxel-induced neuropathy in the Spanish population.
Topics: Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Genetic Markers; Genotype; Humans; Paclitaxel; Peripheral Nervous System Diseases; Spain | 2018 |
Single Nucleotide Polymorphisms of Paclitaxel-induced Peripheral Sensory Neuropathy in Chinese Han Population.
Topics: Asian People; China; Genotype; Humans; Lim Kinases; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide | 2017 |
Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Carbazoles; Disease Models, Animal; Enzyme Activators; Histocytochemistry; Neuroprotective Agents; Nicotinamide Phosphoribosyltransferase; Paclitaxel; Peripheral Nervous System Diseases; Rats; Treatment Outcome | 2017 |
Ghrelin alleviates paclitaxel-induced peripheral neuropathy by reducing oxidative stress and enhancing mitochondrial anti-oxidant functions in mice.
Topics: Animals; Antioxidants; Ganglia, Spinal; Gene Expression Regulation; Ghrelin; Male; Mice; Mice, Inbred C57BL; Mitochondria; Mitochondrial Proteins; Neuroprotective Agents; Oxidative Stress; Paclitaxel; PC12 Cells; Peripheral Nerves; Peripheral Nervous System Diseases; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rats; Receptors, Ghrelin; RNA, Messenger; Superoxide Dismutase; Uncoupling Protein 2 | 2018 |
OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Genotype; HEK293 Cells; Humans; Hyperalgesia; Inhibitory Concentration 50; Liver-Specific Organic Anion Transporter 1; MCF-7 Cells; Mice; Mice, Inbred DBA; Mice, Knockout; Mice, Transgenic; Organic Anion Transporters; Paclitaxel; Peripheral Nervous System Diseases; Phenotype; Pyrimidines | 2018 |
Orally active Epac inhibitor reverses mechanical allodynia and loss of intraepidermal nerve fibers in a mouse model of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Astrocytes; Disease Models, Animal; Female; Ganglia, Spinal; Guanine Nucleotide Exchange Factors; Hydrazones; Hyperalgesia; Isoxazoles; Male; Mice; Mice, Knockout; Nerve Fibers; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Spinal Cord | 2018 |
Effect of flavonol and its dimethoxy derivatives on paclitaxel-induced peripheral neuropathy in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Flavonols; Free Radical Scavengers; Interleukin-1beta; Male; Mice; Paclitaxel; Peripheral Nervous System Diseases; Tumor Necrosis Factor-alpha | 2018 |
Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.
Topics: Animals; Complement System Proteins; Disease Models, Animal; Hyperalgesia; Immunity, Innate; Nerve Fibers; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Rats; Rats, Inbred F344; Rats, Sprague-Dawley | 2018 |
Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Risk Factors | 2018 |
Nmnat mitigates sensory dysfunction in a
Topics: Animals; Cell Count; Dendrites; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Female; Larva; Male; Microtubules; Nicotinamide-Nucleotide Adenylyltransferase; Nociception; Paclitaxel; Peripheral Nervous System Diseases; Sensory Receptor Cells | 2018 |
Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy.
Topics: Adult; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 2018 |
Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cryotherapy; Female; Follow-Up Studies; Humans; Incidence; Japan; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Prospective Studies; Severity of Illness Index | 2018 |
Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.
Topics: Adult; Aged; Biomarkers; Breast Neoplasms; Female; Histidine; Humans; Magnetic Resonance Spectroscopy; Metabolomics; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Phenylalanine; Threonine | 2018 |
Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Hyperalgesia; Male; Motor Activity; Neuralgia; Paclitaxel; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Psychomotor Performance; Random Allocation; Rats; Rats, Sprague-Dawley; Reaction Time; Time Factors | 2018 |
Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?
Topics: Adult; Aged; Female; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Topics: Aged; Bortezomib; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Multiple Myeloma; Nervous System; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Risk Factors; Taxoids; Vincristine | 2018 |
Targeting Axon Integrity to Prevent Chemotherapy-Induced Peripheral Neuropathy.
Topics: Actin Depolymerizing Factors; Action Potentials; Animals; Antineoplastic Agents; Apoptosis; Axons; Caspase 3; Ganglia, Spinal; HSP27 Heat-Shock Proteins; Humans; Hyperalgesia; Male; Mice, Transgenic; Mitochondria; Mitochondrial Swelling; Myelin Sheath; Nerve Degeneration; Nerve Fibers; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; rhoA GTP-Binding Protein; Signal Transduction | 2019 |
Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors.
Topics: Antineoplastic Agents, Phytogenic; Cancer Survivors; Cost of Illness; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Paclitaxel; Pain; Peripheral Nervous System Diseases; Postural Balance; Quality of Life; Socioeconomic Factors; Stress, Psychological | 2018 |
Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk.
Topics: Acetylcysteine; Animals; Antibodies; Cells, Cultured; Clodronic Acid; Coculture Techniques; Ganglia, Spinal; HMGB1 Protein; Hyperalgesia; Imidazoles; Macrophages; Male; Membrane Proteins; Mice; Minocycline; Neurons; p300-CBP Transcription Factors; Paclitaxel; Peripheral Nervous System Diseases; Phosphoproteins; Phosphorylation; Proline; Pyridines; Pyruvates; Reactive Oxygen Species; Receptor for Advanced Glycation End Products; Receptors, CXCR4; Recombinant Proteins; Sciatic Nerve; Thiocarbamates; Thrombomodulin; Up-Regulation | 2018 |
Beneficial effects of Gelsemium-based treatment against paclitaxel-induced painful symptoms.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Dose-Response Relationship, Drug; Gelsemium; Hyperalgesia; Male; Paclitaxel; Pain; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Plant Extracts; Rats; Rats, Sprague-Dawley; Sciatic Nerve | 2018 |
Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Body Mass Index; Body Surface Area; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Risk Factors | 2018 |
Tamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C/extracellular signal-regulated kinase pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Humans; Hyperalgesia; Male; Mammary Neoplasms, Experimental; MAP Kinase Signaling System; Mice, Inbred BALB C; Paclitaxel; Peripheral Nervous System Diseases; Protein Kinase C; Tamoxifen; Vincristine | 2018 |
A light-gated potassium channel for sustained neuronal inhibition.
Topics: Action Potentials; Animals; Female; Hyperalgesia; Light; Male; Mice, Inbred C57BL; Neurons; Optogenetics; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Recombinant Fusion Proteins; Zebrafish | 2018 |
Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cohort Studies; Docetaxel; Female; Humans; Incidence; Medicare; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; SEER Program; United States | 2019 |
Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Retrospective Studies; Spain | 2019 |
Monoclonal Antibody Targeting the Matrix Metalloproteinase 9 Prevents and Reverses Paclitaxel-Induced Peripheral Neuropathy in Mice.
Topics: Animals; Antibodies, Monoclonal; Cells, Cultured; Disease Models, Animal; Female; Ganglia, Spinal; Hyperalgesia; Immunologic Factors; Male; Matrix Metalloproteinase 9; Mice; Neuralgia; Neurons; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases | 2019 |
Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbamates; Cell Line, Tumor; Drug Repositioning; Humans; KCNQ Potassium Channels; Male; Neuralgia; Neurons; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Phenylenediamines; Random Allocation; Rats, Sprague-Dawley | 2019 |
Study of nuclear factor-2 erythroid related factor-2 activator, berberine, in paclitaxel induced peripheral neuropathy pain model in rats.
Topics: Animals; Berberine; Glutathione; Lipid Peroxidation; Male; Malondialdehyde; Models, Animal; Neuralgia; NF-E2-Related Factor 2; Oxidative Stress; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; RNA, Messenger; Sciatic Nerve; Superoxide Dismutase | 2019 |
BDNF Val66Met is Associated with Pre-existing but not with Paclitaxel-induced Peripheral Neuropathy in an Israeli Cohort of Breast Cancer Patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain-Derived Neurotrophic Factor; Breast Neoplasms; Breast Neoplasms, Male; Cohort Studies; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Israel; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Polymerase Chain Reaction; Polymorphism, Single Nucleotide | 2018 |
Circulating microRNA and automated motion analysis as novel methods of assessing chemotherapy-induced peripheral neuropathy in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Automation; Behavior, Animal; Biomarkers; Circulating MicroRNA; Disease Models, Animal; Ganglia, Spinal; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Movement; Nerve Degeneration; Paclitaxel; Peripheral Nervous System Diseases; Sciatic Nerve | 2019 |
Cisplatin educates CD8+ T cells to prevent and resolve chemotherapy-induced peripheral neuropathy in mice.
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cisplatin; Disease Models, Animal; Female; Hyperalgesia; Male; Mice, Transgenic; Paclitaxel; Pain; Peripheral Nervous System Diseases | 2019 |
Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Breast Neoplasms; Case-Control Studies; Constitutive Androstane Receptor; Docetaxel; Female; Glucuronosyltransferase; Humans; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prognosis; Receptors, Cytoplasmic and Nuclear | 2019 |
Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Survivors; Cohort Studies; Exercise; Exercise Therapy; Female; Humans; Male; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2019 |
Preventive hypothermia as a neuroprotective strategy for paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Astrocytes; Electrophysiological Phenomena; Hypothermia, Induced; Macrophage Activation; Male; Mice; Mice, Inbred NOD; Mice, SCID; Microglia; Neuroprotection; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Regional Blood Flow; Sciatic Nerve | 2019 |
Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Female; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Oxaliplatin; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Surveys and Questionnaires | 2019 |
Prevention of paclitaxel-induced neuropathy by formulation approach.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Cell Line, Tumor; Drug Compounding; Humans; Liposomes; Liver; Lung; Male; Muscles; Nanoparticles; Paclitaxel; Peripheral Nervous System Diseases; Rats, Sprague-Dawley; Skin; Spinal Cord; Tissue Distribution | 2019 |
Spinal blockage of CXCL1 and its receptor CXCR2 inhibits paclitaxel-induced peripheral neuropathy in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemokine CXCL1; Ganglia, Spinal; Mice; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Quinoxalines; Receptors, Interleukin-8B; Signal Transduction; Spinal Cord; Thiazolidinediones | 2019 |
Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Oncologists; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Self Report; Young Adult | 2019 |
Search of anti-allodynic compounds from Plantaginis Semen, a crude drug ingredient of Kampo formula "Goshajinkigan".
Topics: Animals; Drugs, Chinese Herbal; Hyperalgesia; Iridoid Glucosides; Iridoids; Lactones; Male; Medicine, Kampo; Mice; Mice, Inbred C57BL; Paclitaxel; Peripheral Nervous System Diseases; Plant Extracts; Plantago | 2019 |
Macrophage Toll-like Receptor 9 Contributes to Chemotherapy-Induced Neuropathic Pain in Male Mice.
Topics: Animals; Antineoplastic Agents; Female; Hyperalgesia; Macrophages; Male; Mice; Neuralgia; Paclitaxel; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Toll-Like Receptor 9 | 2019 |
The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal.
Topics: A549 Cells; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Tolerance; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Nicotine; Nicotinic Agonists; Paclitaxel; Peripheral Nervous System Diseases; Piperazines; Reward | 2019 |
Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy.
Topics: Adult; Aged; Albumins; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Cohort Studies; Compression Bandages; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gloves, Surgical; Humans; Japan; Mastectomy, Segmental; Middle Aged; Paclitaxel; Patient Safety; Peripheral Nervous System Diseases; Primary Prevention; Prognosis; Prospective Studies; Statistics, Nonparametric; Treatment Outcome | 2019 |
Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models | 2012 |
Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
Topics: Aged; Analgesics, Opioid; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; gamma-Aminobutyric Acid; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Pregabalin; Retrospective Studies | 2013 |
Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies.
Topics: Activating Transcription Factor 3; Animals; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Ganglia, Spinal; Glucose; Male; Mice; Mice, Transgenic; Neuroprotective Agents; Paclitaxel; Peptide Fragments; Peripheral Nervous System Diseases; Rats; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.
Topics: Animals; Female; Furans; Ketones; Mice; Mice, Inbred BALB C; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Random Allocation; Tubulin Modulators | 2013 |
Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Axonal Transport; Axons; Dose-Response Relationship, Drug; Epothilones; Furans; Ketones; Kinesins; Loligo; Microtubules; Paclitaxel; Peripheral Nervous System Diseases; Time Factors; Tubulin; Tubulin Modulators; Vincristine | 2013 |
Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calcium; Chemokine CCL2; Female; Ganglia, Spinal; Immunohistochemistry; Injections, Spinal; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Physical Stimulation; Posterior Horn Cells; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, CCR2; Sensory Receptor Cells | 2013 |
Corneal innervation as a window to peripheral neuropathies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Biopsy; Cornea; Cranial Nerve Diseases; Male; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Ophthalmic Nerve; Paclitaxel; Peripheral Nervous System Diseases; Skin | 2013 |
Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Receptors, Eph Family | 2013 |
Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Paclitaxel; Pennsylvania; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids | 2013 |
[Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy].
Topics: Antineoplastic Agents; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pregabalin; Retrospective Studies | 2013 |
Neurosteroid 3α-androstanediol efficiently counteracts paclitaxel-induced peripheral neuropathy and painful symptoms.
Topics: Action Potentials; Androstane-3,17-diol; Animals; Antineoplastic Agents, Phytogenic; Hyperalgesia; Male; Nerve Fibers; Neural Conduction; Neuralgia; Neuroprotective Agents; Paclitaxel; Pain; Pain Measurement; Peripheral Nerves; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2013 |
STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.
Topics: Adenocarcinoma; Animals; Antigens, Polyomavirus Transforming; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Dosage Calculations; Estrenes; Female; Humans; Hyperalgesia; Lung Neoplasms; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Paclitaxel; Peripheral Nervous System Diseases; Rats; Survival Analysis; Transplantation, Heterologous | 2013 |
Role of nerve growth factor-tyrosine kinase receptor A signaling in paclitaxel-induced peripheral neuropathy in rats.
Topics: Animals; Base Sequence; Brain-Derived Neurotrophic Factor; DNA Primers; Male; Nerve Growth Factor; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Receptor, trkA; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy.
Topics: Action Potentials; Animals; Ganglia, Spinal; Gene Expression Regulation; Ion Channels; Male; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells | 2014 |
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Female; Genome-Wide Association Study; Humans; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Taxoids | 2014 |
[Cancer, pain and treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Humans; Neoplasms; Paclitaxel; Pain; Pain Management; Paraneoplastic Polyneuropathy; Peripheral Nervous System Diseases | 2014 |
Peptidergic intraepidermal nerve fibers in the skin contribute to the neuropathic pain in paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calcitonin Gene-Related Peptide; Epidermis; Male; Nerve Degeneration; Nerve Fibers; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Substance P | 2014 |
Probing for chemotherapy-induced peripheral neuropathy in live dorsal root ganglion neurons with atomic force microscopy.
Topics: Animals; Antineoplastic Agents; Biomechanical Phenomena; Cells, Cultured; Cytoskeleton; Elastic Modulus; Ganglia, Spinal; Humans; Mice; Mice, Inbred C57BL; Microscopy, Atomic Force; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Vincristine | 2014 |
CX3CL1-mediated macrophage activation contributed to paclitaxel-induced DRG neuronal apoptosis and painful peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Chemokine CX3CL1; Ganglia, Spinal; Macrophage Activation; Macrophages; Male; Neurons; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Up-Regulation | 2014 |
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP2C8; Drug Resistance, Neoplasm; Female; Genetic Heterogeneity; Genetic Predisposition to Disease; Genotype; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Young Adult | 2014 |
Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Astrocytes; Disease Models, Animal; Ganglia, Spinal; Gene Expression Regulation; Male; Myeloid Differentiation Factor 88; Nerve Tissue Proteins; Neurons; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Physical Stimulation; Polysaccharides; Rats; Rats, Sprague-Dawley; Signal Transduction; Time Factors; Toll-Like Receptor 4 | 2014 |
Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy.
Topics: Adult; Antineoplastic Agents; Brazil; Cross-Sectional Studies; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Psychometrics; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2014 |
The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model.
Topics: Animals; Cisplatin; Disease Models, Animal; Hyperalgesia; Hypoglycemic Agents; Metformin; Mice, Inbred C57BL; Nerve Fibers; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Protective Agents | 2014 |
Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer.
Topics: Adult; Aged; Albumins; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 2014 |
The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cells, Cultured; Disease Models, Animal; Drug Administration Schedule; Drugs, Chinese Herbal; Female; Ganglia, Spinal; Gene Expression Profiling; Gene Expression Regulation; Hyperalgesia; Mice; Mice, Transgenic; Mitochondria; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Rats; Rats, Inbred F344; Sensory Receptor Cells; Time Factors; TRPV Cation Channels | 2014 |
Paclitaxel-induced hyposensitivity to nociceptive chemical stimulation in mice can be prevented by treatment with minocycline.
Topics: Animals; Breast Neoplasms; Female; Formaldehyde; Humans; Hyperalgesia; Mice; Minocycline; Nociception; Paclitaxel; Peripheral Nervous System Diseases | 2014 |
Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Base Sequence; Breast Neoplasms; Cytochrome P-450 CYP3A; Enzyme Stability; Exome; Female; HEK293 Cells; Humans; Middle Aged; Molecular Sequence Data; Paclitaxel; Peripheral Nervous System Diseases; Sequence Analysis, DNA | 2015 |
Genitofemoral neuropathy after pelvic lymphadenectomy in patients with uterine corpus cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carboplatin; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Hysterectomy; Incidence; Laparoscopy; Lymph Node Excision; Middle Aged; Ovariectomy; Paclitaxel; Pelvis; Peripheral Nerve Injuries; Peripheral Nervous System Diseases; Recovery of Function; Salpingectomy; Sensation Disorders; Time Factors; Uterine Neoplasms | 2015 |
Up-regulation of CX3CL1 via Nuclear Factor-κB-dependent Histone Acetylation Is Involved in Paclitaxel-induced Peripheral Neuropathy.
Topics: Acetylation; Animals; Antineoplastic Agents, Phytogenic; Chemokine CX3CL1; Cytokines; Histones; Hyperalgesia; Male; NF-kappa B; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Pyrrolidines; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Spinal Cord; Thiocarbamates; Transcription Factor RelA | 2015 |
Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Genotype; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Genetic; tau Proteins | 2014 |
RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1.
Topics: Antineoplastic Agents; Extracellular Matrix Proteins; Genotype; GPI-Linked Proteins; Humans; Paclitaxel; Peripheral Nervous System Diseases; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Transcription Factors | 2015 |
Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients.
Topics: Adult; Aged; Analgesics; Antineoplastic Agents, Phytogenic; Duloxetine Hydrochloride; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Thiophenes; Treatment Outcome | 2015 |
An exercise regimen prevents development paclitaxel induced peripheral neuropathy in a mouse model.
Topics: Action Potentials; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Male; Mice; Neural Conduction; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Physical Conditioning, Animal | 2015 |
Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Case-Control Studies; Diabetes Complications; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Risk Factors; Severity of Illness Index; Time Factors | 2015 |
Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Female; Humans; Liposomes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Treatment Outcome; Tumor Burden; Uterine Cervical Neoplasms | 2015 |
[A case of Paclitaxel-induced peripheral neuropathy successfully treated with duloxetine].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Duloxetine Hydrochloride; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Thiophenes; Trastuzumab | 2015 |
Sensory neuron subpopulation-specific dysregulation of intracellular calcium in a rat model of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calcium; Disease Models, Animal; Ganglia, Spinal; Intracellular Space; Male; Membrane Potentials; Nociceptive Pain; Nociceptors; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Rats, Sprague-Dawley; Skin; Touch | 2015 |
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Carrier Proteins; Cell Line, Tumor; Cell Survival; DEAD-box RNA Helicases; Eye Proteins; Genome-Wide Association Study; Humans; Induced Pluripotent Stem Cells; Neoplasm Proteins; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-bcr | 2015 |
MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Ganglia, Spinal; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neurons; NF-kappa B; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Toll-Like Receptor 4 | 2015 |
Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance).
Topics: Antineoplastic Agents, Phytogenic; Case-Control Studies; Charcot-Marie-Tooth Disease; Female; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Models, Genetic; Mutation; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Polymorphism, Single Nucleotide; Rho Guanine Nucleotide Exchange Factors | 2015 |
Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Brain-Derived Neurotrophic Factor; Breast Neoplasms; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2015 |
Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calcium Signaling; Cell Line, Tumor; Cell Survival; Decanoic Acids; Female; Ganglia, Spinal; Humans; Hydroxy Acids; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Neurons; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Primary Cell Culture; Sciatic Nerve; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Paclitaxel alters sensory nerve biomechanical properties.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Biomechanical Phenomena; Elastic Modulus; Microtubules; Paclitaxel; Peripheral Nervous System Diseases; Rats, Sprague-Dawley | 2015 |
Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-μ.
Topics: Analgesics; Animals; Antineoplastic Agents, Phytogenic; Cisplatin; Disease Models, Animal; Female; Ganglia, Spinal; Humans; Hyperalgesia; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Mitochondria; Paclitaxel; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Sulfonamides; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2015 |
Paclitaxel-induced peripheral neuropathy increases substance P release in rat spinal cord.
Topics: Animals; Dose-Response Relationship, Drug; Gene Expression Regulation; Hyperalgesia; Male; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Receptors, Calcitonin Gene-Related Peptide; Spinal Cord; Substance P | 2016 |
Effects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule-Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral Neuropathy.
Topics: Acetylation; Animals; Axons; Female; Furans; Ketones; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Microtubules; Myelin Sheath; Paclitaxel; Peripheral Nervous System Diseases; Sciatic Nerve; Sciatic Neuropathy; Tubulin | 2016 |
Impact of Genetic Reduction of NMNAT2 on Chemotherapy-Induced Losses in Cell Viability In Vitro and Peripheral Neuropathy In Vivo.
Topics: Animals; Antineoplastic Agents; Cell Survival; Female; Mice; Mice, Mutant Strains; Nicotinamide-Nucleotide Adenylyltransferase; Paclitaxel; Peripheral Nervous System Diseases; Pregnancy; Vincristine | 2016 |
Nerve growth factor alters microtubule targeting agent-induced neurotransmitter release but not MTA-induced neurite retraction in sensory neurons.
Topics: Animals; Antineoplastic Agents; Calcitonin Gene-Related Peptide; Capsaicin; Epothilones; Ganglia, Spinal; Male; Microtubules; Nerve Growth Factor; Neurites; Neuropeptides; Neurotransmitter Agents; Paclitaxel; Peripheral Nervous System Diseases; Potassium; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells | 2016 |
CX3CR1-Mediated Akt1 Activation Contributes to the Paclitaxel-Induced Painful Peripheral Neuropathy in Rats.
Topics: Animals; CX3C Chemokine Receptor 1; Male; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, Chemokine | 2016 |
Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy.
Topics: Anesthetics; Animals; Antibodies; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Cell Movement; Chemokine CCL2; Clodronic Acid; Disease Models, Animal; Drug Administration Routes; Ganglia, Spinal; GAP-43 Protein; Hyperalgesia; Isoflurane; Lipopolysaccharides; Macrophages; Male; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Spinal Cord; Spleen; Time Factors; Tumor Necrosis Factor-alpha; Ubiquitin Thiolesterase | 2016 |
Identification of fluocinolone acetonide to prevent paclitaxel-induced peripheral neuropathy.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Axons; Cell Line, Tumor; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; Fluocinolone Acetonide; Ganglia, Spinal; Mice; Nerve Fibers; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2016 |
Paclitaxel-induced increase in NCX activity in subpopulations of nociceptive afferents: A protective mechanism against chemotherapy-induced peripheral neuropathy?
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Calcium; Calcium Signaling; Male; Neurons, Afferent; Nociceptors; Paclitaxel; Peripheral Nervous System Diseases; Phenyl Ethers; Rats, Sprague-Dawley; Sodium-Calcium Exchanger; Thiourea | 2016 |
Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Dose-Response Relationship, Drug; Electrophysiology; Epothilones; Female; Furans; Ganglia, Spinal; Ketones; Mice; Mice, Inbred BALB C; Microtubules; Paclitaxel; Peripheral Nervous System Diseases; Sciatic Nerve; Time Factors; Tissue Distribution; Tubulin Modulators | 2016 |
Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity.
Topics: Analgesics; Animals; Antineoplastic Agents, Phytogenic; Carnosine; Cell Line, Tumor; Cell Survival; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Neoplasms; Organometallic Compounds; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Tumor Burden; Zinc Compounds | 2016 |
Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Astrocytes; Cells, Cultured; Disease Models, Animal; Disease Progression; Ganglia, Spinal; Hyperalgesia; Lumbar Vertebrae; Male; Microglia; Neurons; Oxidative Stress; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats, Sprague-Dawley; Reactive Oxygen Species; Spinal Cord | 2016 |
Paclitaxel causes degeneration of both central and peripheral axon branches of dorsal root ganglia in mice.
Topics: Animals; Antineoplastic Agents; Axons; Disease Models, Animal; Female; Ganglia, Spinal; Male; Mice, Inbred C57BL; Microscopy, Electron; Nerve Degeneration; Paclitaxel; Peripheral Nervous System Diseases; Sciatic Nerve; Spinal Cord | 2016 |
Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents; Disease Models, Animal; Ganglia, Spinal; HMGB1 Protein; Hyperalgesia; Male; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Recombinant Proteins; Sciatic Nerve; Thrombomodulin; Toll-Like Receptor 4; Vincristine | 2016 |
Structural Basis for Induction of Peripheral Neuropathy by Microtubule-Targeting Cancer Drugs.
Topics: Animals; Antineoplastic Agents; Axonal Transport; Epothilones; Furans; Humans; Ketones; Mice; Microtubules; Mitochondria; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Sciatic Nerve; Tubulin Modulators; Vincristine | 2016 |
Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases | 2016 |
Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle Proteins; Charcot-Marie-Tooth Disease; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Nerve Tissue; Paclitaxel; Peripheral Nervous System Diseases | 2016 |
Dorsal root ganglion neurons become hyperexcitable and increase expression of voltage-gated T-type calcium channels (Cav3.2) in paclitaxel-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Azabicyclo Compounds; Benzamides; Calcitonin Gene-Related Peptide; Calcium Channel Blockers; Calcium Channels, T-Type; Disease Models, Animal; Ganglia, Spinal; Gene Expression Regulation; Humans; Hyperalgesia; Male; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Spinal Cord; Sulfonamides; Toll-Like Receptor 4 | 2017 |
Rikkunshito prevents paclitaxel-induced peripheral neuropathy through the suppression of the nuclear factor kappa B (NFκB) phosphorylation in spinal cord of mice.
Topics: Animals; Drugs, Chinese Herbal; Hyperalgesia; Male; Mice; Mice, Inbred ICR; Neuralgia; Neuroprotective Agents; NF-kappa B; Paclitaxel; Peripheral Nervous System Diseases; Phosphorylation; Signal Transduction; Spinal Cord | 2017 |
Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
Topics: Administration, Intravenous; Anemia; Antineoplastic Agents; Blood Transfusion; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Drug Costs; Female; Filgrastim; Hematologic Agents; Hospitalization; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2017 |
Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study.
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Liver; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Pharmacoepidemiology; Platelet Aggregation Inhibitors; Retrospective Studies; Severity of Illness Index; Ticlopidine | 2017 |
Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Phytogenic; Ganglia, Spinal; Gene Expression; Matrix Metalloproteinase 3; Paclitaxel; Peripheral Nervous System Diseases; Rats; Receptors, Cell Surface; Up-Regulation | 2008 |
Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Axons; Cells, Cultured; Cisplatin; Frataxin; Ganglia, Spinal; Iron-Binding Proteins; Membrane Potentials; Mitochondria; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Rats; Schwann Cells; Sensory Receptor Cells; Thioctic Acid | 2008 |
Neurotropin reverses paclitaxel-induced neuropathy without affecting anti-tumour efficacy.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Phytogenic; Axons; Cell Line, Tumor; Cold Temperature; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neoplasm Transplantation; Neurites; Paclitaxel; Peripheral Nervous System Diseases; Polysaccharides; Rats; Rats, Sprague-Dawley | 2009 |
Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Incidence; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Surveys and Questionnaires | 2009 |
Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Disease Models, Animal; Drug Administration Schedule; Female; Ganglia, Spinal; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Weight Loss | 2009 |
[Clinical features of paclitaxel-induced peripheral neuropathy and role of Gosya-jinki-gan].
Topics: Breast Neoplasms; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Plant Extracts; Surveys and Questionnaires; Vitamins | 2009 |
Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; G(M1) Ganglioside; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Sensation | 2009 |
Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
Topics: Acetylcarnitine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cell Growth Processes; Cell Line, Tumor; Female; Flow Cytometry; Humans; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Receptor, Nerve Growth Factor; Receptor, trkA | 2009 |
Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit.
Topics: Administration, Oral; Amines; Analgesics, Non-Narcotic; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Behavior, Animal; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Ganglia, Spinal; Gene Expression; Injections, Spinal; Male; Mice; Mice, Inbred C57BL; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pain; Peripheral Nervous System Diseases; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord; Vincristine | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Differential effects of paclitaxel treatment on cognitive functioning and mechanical sensitivity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cognition; Cognition Disorders; Conditioning, Operant; Male; Paclitaxel; Peripheral Nervous System Diseases; Physical Stimulation; Rats; Rats, Long-Evans; Reaction Time | 2009 |
Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.
Topics: Analgesics; Analysis of Variance; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Comorbidity; Female; Follow-Up Studies; Humans; Logistic Models; Multivariate Analysis; Neuralgia; Odds Ratio; Paclitaxel; Patient Acceptance of Health Care; Peripheral Nervous System Diseases; Risk Factors | 2009 |
Tracing the incidence of paclitaxel-induced peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Reproducibility of Results | 2009 |
[A case of paclitaxel-induced peripheral neuropathy successfully treated by H2-blocker, lafutidine].
Topics: Acetamides; Aged; Antineoplastic Agents, Phytogenic; Female; Histamine H2 Antagonists; Humans; Paclitaxel; Peripheral Nervous System Diseases; Piperidines; Pyridines; Stomach Neoplasms | 2009 |
Phenyl N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Behavior, Animal; Body Weight; Cyclic N-Oxides; Dose-Response Relationship, Drug; Free Radical Scavengers; Hypnotics and Sedatives; Male; Neuroprotective Agents; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2010 |
Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats.
Topics: Analgesics; Animals; Male; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Rats; Rats, Wistar | 2010 |
Comparative study of peripheral neurotoxicity after injection of two different paclitaxel formulations in rats.
Topics: Action Potentials; Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Electrophysiology; Injections; Male; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Sensory Receptor Cells; Sural Nerve | 2010 |
Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Topics: Animals; Behavior, Animal; Biotransformation; Cannabinoids; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Hydrazines; Indoles; Male; Mice; Mice, Knockout; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Spinal Nerves | 2010 |
Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Methanol; Ovarian Neoplasms; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; TRPM Cation Channels | 2010 |
Persistent mobility disability after neurotoxic chemotherapy.
Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disability Evaluation; Female; Gait Disorders, Neurologic; Humans; Mastectomy; Mobility Limitation; Paclitaxel; Peripheral Nervous System Diseases; Postural Balance | 2010 |
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Body Weight; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Ganglia, Spinal; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nerve Fibers, Myelinated; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sciatic Nerve | 2010 |
Invited commentary.
Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disability Evaluation; Female; Gait Disorders, Neurologic; Humans; Mastectomy; Mobility Limitation; Paclitaxel; Peripheral Nervous System Diseases; Postural Balance; Research Design | 2010 |
Role of satellite cell-derived L-serine in the dorsal root ganglion in paclitaxel-induced painful peripheral neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cold Temperature; Ganglia, Spinal; Hyperalgesia; Male; Neural Conduction; Paclitaxel; Pain; Peripheral Nervous System Diseases; Phosphoglycerate Dehydrogenase; Rats; Rats, Sprague-Dawley; Satellite Cells, Perineuronal; Serine; Stereoisomerism; Tail; Touch | 2011 |
Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cross-Sectional Studies; Female; Humans; Hypesthesia; Middle Aged; Nervous System Diseases; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Taxoids | 2011 |
Involvement of substance P in peripheral neuropathy induced by paclitaxel but not oxaliplatin.
Topics: Animals; Cells, Cultured; Ganglia, Spinal; Male; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Substance P | 2011 |
Falls in persons with chemotherapy-induced peripheral neuropathy.
Topics: Accidental Falls; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Docetaxel; Female; Humans; Logistic Models; Male; Middle Aged; Muscle Weakness; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Population Surveillance; Postural Balance; Prospective Studies; Risk Factors; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2012 |
Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Area Under Curve; Chi-Square Distribution; Female; Humans; Middle Aged; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Prospective Studies; Statistics, Nonparametric; Surveys and Questionnaires; Syndrome | 2011 |
Anti-nociceptive effect of kinin B₁ and B₂ receptor antagonists on peripheral neuropathy induced by paclitaxel in mice.
Topics: Analgesics; Animals; Bradykinin; Bradykinin B1 Receptor Antagonists; Bradykinin B2 Receptor Antagonists; Hyperalgesia; Kinins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; Peripheral Nervous System Diseases; Receptor, Bradykinin B1; Receptor, Bradykinin B2; RNA, Messenger | 2011 |
Abnormal muscle afferent function in a model of Taxol chemotherapy-induced painful neuropathy.
Topics: Action Potentials; Afferent Pathways; Animals; Antineoplastic Agents; Disease Models, Animal; Male; Muscle, Skeletal; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2011 |
Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice.
Topics: Analgesics; Animals; Behavior, Animal; Cannabidiol; Cold Temperature; Disease Models, Animal; Female; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Physical Stimulation; Sex Factors; Time Factors | 2011 |
Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Surveys and Questionnaires; Taxoids | 2012 |
The effects of opioid receptor antagonists on electroacupuncture-produced anti-allodynia/hyperalgesia in rats with paclitaxel-evoked peripheral neuropathy.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Electroacupuncture; Hyperalgesia; Male; Naltrexone; Narcotic Antagonists; Paclitaxel; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Random Allocation; Rats; Rats, Sprague-Dawley; Somatostatin | 2011 |
Antinociceptive efficacy of verticinone in murine models of inflammatory pain and paclitaxel induced neuropathic pain.
Topics: Analgesics; Animals; Cevanes; Disease Models, Animal; Inflammation; Mice; Mice, Inbred ICR; Paclitaxel; Pain; Peripheral Nervous System Diseases | 2011 |
Comparison of peripheral neuropathy induced by standard and nanoparticle albumin-bound paclitaxel in rats.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Cold Temperature; Dose-Response Relationship, Drug; Hand Strength; Hyperalgesia; Male; Motor Skills; Nanoparticles; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2011 |
Lithium attenuates peripheral neuropathy induced by paclitaxel in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Lithium Chloride; Male; Motor Neurons; Neural Conduction; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2012 |
Global inhibition of reactive oxygen species (ROS) inhibits paclitaxel-induced painful peripheral neuropathy.
Topics: Animals; Cyclic N-Oxides; Free Radical Scavengers; Male; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Spin Labels | 2011 |
[ABCB1 polymorphisms in patients with Charcot-Marie-Tooth disease. A possible relationship with neurotoxicity due to cytostatic treatment].
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Charcot-Marie-Tooth Disease; Colonic Neoplasms; Cytostatic Agents; Disease Susceptibility; Female; Genotype; Humans; Multidrug Resistance-Associated Proteins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide | 2012 |
Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Cell Respiration; Male; Microscopy, Electron, Transmission; Mitochondria; Motor Neurons; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells | 2011 |
Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Young Adult | 2013 |
Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Pennsylvania; Peripheral Nervous System Diseases; Self Care; Taxoids; Young Adult | 2012 |
TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism.
Topics: Acetanilides; Animals; Calcitonin Gene-Related Peptide; Capsaicin; Cold Temperature; Drug Hypersensitivity; Glutathione; Hyperalgesia; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Paclitaxel; Peripheral Nervous System Diseases; Purines; Pyrroles; Transient Receptor Potential Channels; TRPA1 Cation Channel; TRPV Cation Channels | 2012 |
Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Electromyography; Evoked Potentials, Motor; Female; Genital Neoplasms, Female; Humans; Longitudinal Studies; Middle Aged; Neural Conduction; Neurologic Examination; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases; Taxoids; Time Factors | 2012 |
Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.
Topics: Analgesics; Animals; Benzoxazines; Cannabinoids; Dose-Response Relationship, Drug; Hyperalgesia; Inflammation Mediators; Male; Morpholines; Naphthalenes; Neuroglia; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Spinal Cord | 2012 |
Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.
Topics: Animals; Antineoplastic Agents, Phytogenic; Astrocytes; Benzofurans; Blotting, Western; CD11b Antigen; Cricetinae; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Profiling; Glial Fibrillary Acidic Protein; Humans; Hyperalgesia; Image Processing, Computer-Assisted; Immunohistochemistry; Lipopolysaccharides; Male; Mice; Mice, Knockout; Microscopy, Confocal; Neuroglia; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Physical Stimulation; Piperidines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptor, Cannabinoid, CB2; Spinal Cord; Toll-Like Receptor 2 | 2012 |
Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.
Topics: Acute Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Surveys and Questionnaires; Syndrome | 2012 |
Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Drug Interactions; Duloxetine Hydrochloride; Etodolac; gamma-Aminobutyric Acid; Hyperalgesia; Male; Mexiletine; Mice; Paclitaxel; Peripheral Nervous System Diseases; Pregabalin; Thiophenes; Tissue Distribution | 2012 |
Analgesic effect of magnetic stimulation on paclitaxel-induced peripheral neuropathic pain in mice.
Topics: Analgesia; Analgesics; Animals; Hyperalgesia; Magnetic Field Therapy; Male; Mice; Mice, Inbred ICR; Neuralgia; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases | 2012 |
Profound and persistent painful paclitaxel peripheral neuropathy in a premenopausal patient.
Topics: Adult; Antineoplastic Agents, Phytogenic; Brain; Breast Neoplasms; Female; Humans; Magnetic Resonance Imaging; Neuroimaging; Paclitaxel; Peripheral Nervous System Diseases | 2011 |
Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Isoforms; Risk; Tubulin; Tubulin Modulators | 2012 |
Electrophysiological features of the mouse tail nerves and their changes in chemotherapy induced peripheral neuropathy (CIPN).
Topics: Animals; Antineoplastic Agents, Phytogenic; Biophysics; Disease Models, Animal; Electric Stimulation; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Motor Activity; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Reaction Time; Rotarod Performance Test; Species Specificity; Tail; Time Factors | 2012 |
Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calcium Signaling; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Glycogen Synthase Kinase 3; Lithium; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Phosphodiesterase Inhibitors; Pyridines | 2012 |
Inhibition of paclitaxel-induced decreases in calcium signaling.
Topics: Calcium Signaling; Calpain; Cell Line, Tumor; Enzyme Activation; Humans; Immunoblotting; Lithium; Microscopy, Confocal; Microtubules; Molecular Imaging; Neuronal Calcium-Sensor Proteins; Neuropeptides; Paclitaxel; Peripheral Nervous System Diseases; Phosphodiesterase Inhibitors; Proteolysis; Pyridines; Tubulin Modulators | 2012 |
[A case of paclitaxel-induced peripheral neuropathy successfully treated with pregabalin].
Topics: Antineoplastic Combined Chemotherapy Protocols; gamma-Aminobutyric Acid; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Pregabalin | 2012 |
The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Benzylamines; Chromones; Cisplatin; Cryopyrin-Associated Periodic Syndromes; Cyclams; Disease Models, Animal; Heterocyclic Compounds; Hyperalgesia; Indoles; Male; Paclitaxel; Peripheral Nervous System Diseases; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Receptors, CXCR4; Signal Transduction; Time Factors; Treatment Outcome | 2012 |
Successful treatment by adding duloxetine to pregabalin for peripheral neuropathy induced by paclitaxel.
Topics: Duloxetine Hydrochloride; Humans; Paclitaxel; Peripheral Nervous System Diseases; Pregabalin; Quality of Life; Thiophenes | 2013 |
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Female; Genome-Wide Association Study; Humans; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Regulatory Factor X Transcription Factors; Transcription Factors | 2013 |
Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.
Topics: Aged; Antineoplastic Agents, Phytogenic; Biopsy; Female; Humans; Male; Mechanoreceptors; Middle Aged; Motor Skills; Nerve Fibers; Neurotoxicity Syndromes; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Physical Stimulation; Pilot Projects; Sensory Thresholds; Skin; Thermosensing; Touch; Vincristine | 2013 |
[Role of satellite cell-derived L-serine in the dorsal root ganglion in paclitaxel-induced peripheral neuropathy].
Topics: Animals; Antineoplastic Agents, Phytogenic; Ganglia, Spinal; Humans; Hyperalgesia; Paclitaxel; Peripheral Nervous System Diseases; Rats; Satellite Cells, Perineuronal; Serine | 2013 |
[Targeting Ca(v)3.2 T-type calcium channels as a therapeutic strategy for chemotherapy-induced neuropathic pain].
Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Calcium Channels, T-Type; Dinoprostone; Humans; Hydrogen Sulfide; Molecular Targeted Therapy; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases | 2013 |
WldS mice are resistant to paclitaxel (taxol) neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Cells, Cultured; Female; Ganglia, Spinal; Genetic Predisposition to Disease; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Neurons, Afferent; Paclitaxel; Peripheral Nervous System Diseases; Phenotype; Wallerian Degeneration | 2002 |
Toxic neuropathy in patients with pre-existing neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Lupus Erythematosus, Discoid; Lymphoma; Male; Middle Aged; Neural Conduction; Oropharyngeal Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Severity of Illness Index; Thalidomide; Vincristine | 2003 |
Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Evaluation; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pleurodynia, Epidemic; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome; Women's Health | 2003 |
Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurologic Examination; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Body Weight; Cell Survival; Cisplatin; Electrophysiology; Male; Motor Neurons; Neural Conduction; Neurons, Afferent; Oximes; Paclitaxel; Peripheral Nervous System Diseases; Piperidines; Rats | 2003 |
Effects of ganglioside on paclitaxel (Taxol) induced neuropathy in rats.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Electrophysiology; Female; Gangliosides; Neural Conduction; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Probability; Rats; Rats, Wistar; Reference Values; Sciatic Nerve; Sensation | 2003 |
Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2003 |
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ifosfamide; Neurologic Examination; Paclitaxel; Peripheral Nervous System Diseases; Severity of Illness Index; Taxoids; Uterine Cervical Neoplasms | 2003 |
Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids; Treatment Outcome | 2004 |
Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
Topics: Adult; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Narcotics; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Radiation-Protective Agents; Time Factors | 2004 |
Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Cold Temperature; Disease Models, Animal; Female; Hot Temperature; Hyperalgesia; Male; Mice; Mice, Inbred Strains; Paclitaxel; Pain; Peripheral Nervous System Diseases; Physical Stimulation; Species Specificity | 2004 |
Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Calcium; Cation Transport Proteins; Cells, Cultured; Disease Models, Animal; Hyperalgesia; Hypotonic Solutions; Integrins; Ion Channels; Male; Neuralgia; Nociceptors; Oligonucleotides, Antisense; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Signal Transduction; src-Family Kinases; TRPV Cation Channels | 2004 |
Vinorelbine-induced acute reversible peripheral neuropathy in a patient with ovarian carcinoma pretreated with carboplatin and paclitaxel.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Vinblastine; Vinorelbine | 2004 |
[Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Vomiting, Anticipatory | 2004 |
Chemotherapy-induced neuropathy: treatment by decompression of peripheral nerves.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carpal Tunnel Syndrome; Cisplatin; Decompression, Surgical; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand; Humans; Leg; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Nerve Compression Syndromes; Neuralgia; Ovarian Neoplasms; Paclitaxel; Pain Measurement; Paresthesia; Peripheral Nervous System Diseases; Treatment Outcome; Vincristine; Wrist | 2004 |
Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Evaluation; Female; Follow-Up Studies; Humans; Life Tables; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Female; Humans; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Randomized Controlled Trials as Topic | 2004 |
[The efficacy of Shakuyaku-Kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Drug Administration Schedule; Drug Combinations; Drugs, Chinese Herbal; Female; Glycyrrhiza; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Paeonia; Peripheral Nervous System Diseases | 2004 |
Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?
Topics: Adult; Aged; Breast Neoplasms; Cisplatin; Drug Therapy, Combination; Female; Forecasting; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxins; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 2005 |
Prevention of chemotherapy-induced neuropathy: leukemia inhibitory factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Humans; Interleukin-6; Leukemia Inhibitory Factor; Paclitaxel; Peripheral Nervous System Diseases; Proteins; Treatment Outcome | 2005 |
Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Microtubules; Nerve Fibers, Myelinated; Nerve Growth Factor; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Taxoids | 2005 |
Spinal glial glutamate transporters downregulate in rats with taxol-induced hyperalgesia.
Topics: Amino Acid Transport System X-AG; Animals; Antineoplastic Agents, Phytogenic; Cell Communication; Disease Models, Animal; Down-Regulation; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Glutamate Plasma Membrane Transport Proteins; Glutamic Acid; Hyperalgesia; Male; Neuroglia; Nociceptors; Paclitaxel; Peripheral Nervous System Diseases; Posterior Horn Cells; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Symporters; Synaptic Transmission | 2005 |
[A case of recurrent esophageal cancer successfully treated with weekly paclitaxel in combination with radiotherapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Radiotherapy Dosage; Remission Induction | 2005 |
Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Female; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 2006 |
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
Topics: Antineoplastic Agents; Cisplatin; Dose-Response Relationship, Drug; Humans; Microtubules; Motor Neurons; Neurons, Afferent; Neuroprotective Agents; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases; Pilot Projects; Randomized Controlled Trials as Topic; Reproducibility of Results; Vitamin E | 2005 |
The effect of height on paclitaxel nerve damage.
Topics: Action Potentials; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Height; Breast Neoplasms; Female; Humans; Middle Aged; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Peroneal Nerve; Sural Nerve | 2005 |
A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Cannabinoids; Humans; Neoplasms; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases | 2005 |
A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats.
Topics: Analgesics; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Benzoxazines; Cannabinoids; Disease Models, Animal; Hot Temperature; Humans; Hyperalgesia; Male; Morpholines; Naphthalenes; Neuralgia; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Physical Stimulation; Rats; Rats, Wistar; Sensory Thresholds; Touch; Treatment Outcome | 2005 |
Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Disease Progression; Drug Therapy; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Time Factors | 2005 |
Altered discharges of spinal wide dynamic range neurons and down-regulation of glutamate transporter expression in rats with paclitaxel-induced hyperalgesia.
Topics: Amino Acid Transport System X-AG; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Data Interpretation, Statistical; Down-Regulation; Electric Stimulation; Electrophysiology; Evoked Potentials; Hot Temperature; Hyperalgesia; Immunohistochemistry; Male; Neurons; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Physical Stimulation; Posterior Horn Cells; Rats; Rats, Sprague-Dawley; Spinal Cord | 2006 |
Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy.
Topics: Acetylcarnitine; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Male; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2006 |
Peripheral neuropathy in a woman with breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2006 |
Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Behavior, Animal; Male; Microscopy, Electron; Microtubules; Mitochondria; Nerve Fibers, Unmyelinated; Neurons, Afferent; Paclitaxel; Pain; Peripheral Nerves; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2006 |
Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin.
Topics: Amines; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Blotting, Western; Calcium Channels; Cyclohexanecarboxylic Acids; Electric Stimulation; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Ganglia, Spinal; Immunohistochemistry; Ion Channel Gating; Male; Mice; Myelin Sheath; Nerve Fibers, Myelinated; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Epidermis; Hindlimb; Immunohistochemistry; Langerhans Cells; Male; Nerve Fibers; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Ubiquitin Thiolesterase; Vincristine | 2006 |
Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat.
Topics: Activating Transcription Factor 3; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Phytogenic; Biomarkers; Ganglia, Spinal; Glial Fibrillary Acidic Protein; Injections, Intravenous; Lumbosacral Region; Male; Neurons, Afferent; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Thorax; Trigeminal Ganglion | 2006 |
Motor dominant neuropathy induced by adjuvant therapy with adriamycin and cyclophosphamide followed by dose-dense paclitaxel in a breast cancer patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Motor Neuron Disease; Paclitaxel; Peripheral Nervous System Diseases | 2006 |
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Genotype; Humans; Neutropenia; Organic Anion Transporters; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Genetic | 2006 |
Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells.
Topics: Activating Transcription Factor 3; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Phytogenic; CD11b Antigen; Chemotaxis, Leukocyte; Disease Models, Animal; Ganglia, Spinal; Glial Fibrillary Acidic Protein; Hyperalgesia; Injections, Intravenous; Macrophages; Male; Microglia; Neurons, Afferent; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases; Posterior Horn Cells; Rats; Rats, Sprague-Dawley; Satellite Cells, Perineuronal; Schwann Cells | 2007 |
Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2006 |
Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.
Topics: Animals; Apoptosis; Cells, Cultured; Drug Therapy, Combination; Electrophysiology; Endothelial Cells; Humans; Injections, Intramuscular; Lectins; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Paclitaxel; Peripheral Nervous System Diseases; Phosphatidylinositol 3-Kinases; Plasmids; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Renal Circulation; Thalidomide; Vasa Nervorum; Vascular Endothelial Growth Factor A | 2007 |
Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; CD11b Antigen; Cytokines; Disease Models, Animal; Ganglia, Spinal; Genetic Therapy; Hyperalgesia; Injections, Spinal; Interleukin-10; Interleukin-1beta; Male; Meninges; Neuroglia; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Plasmids; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-1; RNA, Messenger; Spinal Cord; Tumor Necrosis Factor-alpha | 2007 |
Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Electrophysiology; Female; Humans; Male; Middle Aged; Paclitaxel; Patient Compliance; Peripheral Nervous System Diseases | 2007 |
Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation.
Topics: Animals; Calcium Signaling; Calpain; Cell Line; Cells, Cultured; Humans; Neuronal Calcium-Sensor Proteins; Neurons; Neuropeptides; Paclitaxel; Peripheral Nervous System Diseases; Phosphatidylinositols; Rats; Signal Transduction; Time Factors | 2007 |
[A case of S-1-resistant recurrent gastric cancer successfully treated with weekly administration of paclitaxel].
Topics: Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Leukopenia; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peripheral Nervous System Diseases; Stomach Neoplasms; Tegafur | 2007 |
Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.
Topics: Acetylcarnitine; Action Potentials; Afferent Pathways; Analgesics; Animals; Antineoplastic Agents; Energy Metabolism; Ganglia, Spinal; Male; Mitochondria; Nerve Fibers, Myelinated; Nerve Fibers, Unmyelinated; Neurons, Afferent; Nociceptors; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Vincristine; Wallerian Degeneration | 2008 |
Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel.
Topics: Activating Transcription Factor 3; Animals; Antineoplastic Agents, Phytogenic; Cell Nucleolus; Cell Size; Disease Models, Animal; Female; Ganglia, Spinal; H-Reflex; Immunohistochemistry; Neural Conduction; Neurons, Afferent; Neuropeptide Y; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Proto-Oncogene Proteins c-jun; Rats; Rats, Wistar; Reaction Time; Up-Regulation | 2007 |
Toxic effects differ in combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2007 |
Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Laryngeal Nerves; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Vinblastine; Vinorelbine; Vocal Cord Paralysis | 2008 |
Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.
Topics: Acetylcarnitine; Animals; Axons; Behavior, Animal; Disease Models, Animal; Drug Interactions; Langerhans Cells; Male; Microscopy, Electron, Transmission; Mitochondria; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Skin | 2008 |
Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Ataxia; Catechols; Cisplatin; Colonic Neoplasms; Drug Evaluation, Preclinical; Female; Humans; Interleukin-6; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neural Conduction; Neuroprotective Agents; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Postural Balance; Rats; Rats, Inbred Strains; Transplantation, Heterologous; Vincristine | 2008 |
Herbal medicine Shakuyaku-kanzo-to reduces paclitaxel-induced painful peripheral neuropathy in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Behavior, Animal; Drug Combinations; Drugs, Chinese Herbal; Glycyrrhiza; Hyperalgesia; Male; Mice; Paclitaxel; Paeonia; Pain; Pain Measurement; Peripheral Nervous System Diseases; Phenylpropionates; Physical Stimulation | 2009 |
Taxol-induced neuropathy: short-term effects of local injection.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Axons; Male; Microscopy, Electron; Microtubules; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases; Rats; Rats, Inbred Strains; Schwann Cells | 1984 |
Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol.
Topics: Animals; Female; Ganglia, Spinal; Injections, Intraperitoneal; Microscopy, Electron; Neural Conduction; Neurotoxins; Paclitaxel; Peripheral Nervous System Diseases; Peroneal Nerve; Rats; Rats, Wistar; Reference Values; Schwann Cells; Sciatic Nerve; Tail | 1995 |
Taxol causes permanent large fiber peripheral nerve dysfunction: a lesson for preventative strategies.
Topics: Aged; Axons; Humans; Male; Nerve Fibers; Paclitaxel; Peripheral Nervous System Diseases | 1993 |
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Electrophysiology; Female; Humans; Male; Middle Aged; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Sensory Thresholds; Severity of Illness Index; Vibration | 1994 |
Neurotoxicity as a possible manifestation of paclitaxel hypersensitivity reactions.
Topics: Breast Neoplasms; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings.
Topics: Electrodiagnosis; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Sural Nerve | 1994 |
Vinorelbine after paclitaxel in breast cancer: cross resistance and cumulative neurotoxicity?
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Vinblastine; Vinorelbine | 1994 |
Peripheral neurotoxicity induced by docetaxel.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1996 |
Peripheral neuropathy secondary to docetaxel (Taxotere)
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Electromyography; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1996 |
Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cause of Death; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Neutrophils; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 1996 |
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.
Topics: Aged; Breast Neoplasms; Cisplatin; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 1995 |
Paclitaxel-induced severe neuropathy in patients with previous radiotherapy to the head and neck region.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Radiotherapy Dosage | 1996 |
Severe neurotoxicity from vinorelbine-paclitaxel combinations.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Vinblastine; Vinorelbine | 1996 |
Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation.
Topics: Antineoplastic Agents, Phytogenic; Extravasation of Diagnostic and Therapeutic Materials; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 1996 |
Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Embryonal; Humans; Leukopenia; Male; Paclitaxel; Peripheral Nervous System Diseases; Salvage Therapy; Testicular Neoplasms; Thrombocytopenia | 1996 |
Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1997 |
Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma; Cause of Death; Drug Hypersensitivity; Endometrial Neoplasms; Female; Fever; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Sepsis; Thrombocytopenia; Treatment Outcome | 1997 |
Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Remission Induction; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Failure; Vinblastine; Vinorelbine | 1998 |
Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Arthralgia; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Muscles; Neuromuscular Diseases; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies | 1998 |
Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Female; Gait; Glutamic Acid; Hot Temperature; Mammary Neoplasms, Experimental; Motor Activity; Paclitaxel; Peripheral Nervous System Diseases; Rats; Sensory Thresholds | 1999 |
Docetaxel neuropathy: a distal axonopathy.
Topics: Antineoplastic Agents, Phytogenic; Axons; Docetaxel; Humans; Male; Middle Aged; Nerve Fibers, Myelinated; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 1999 |
Paclitaxel-induced stomal neuropathy: a unique cause of pain in a patient with ileal conduit.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Humans; Ileum; Male; Middle Aged; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Postoperative Complications; Surgical Stomas; Urinary Bladder Neoplasms; Urinary Diversion | 2000 |
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies | 2001 |
A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Leg; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Proprioception | 2001 |
Leukaemia inhibitory factor abrogates Paclitaxel-induced axonal atrophy in the Wistar rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Calcitonin Gene-Related Peptide; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Ganglia, Spinal; Growth Inhibitors; Immunohistochemistry; Interleukin-6; Leukemia Inhibitory Factor; Lymphokines; Nerve Degeneration; Neural Conduction; Neurons, Afferent; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Substance P | 2001 |
A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Cold Temperature; Disease Models, Animal; Hindlimb; Hot Temperature; Hyperalgesia; Male; Motor Activity; Paclitaxel; Peripheral Nervous System Diseases; Physical Stimulation; Rats; Rats, Sprague-Dawley; Tail | 2001 |
Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cyclic AMP-Dependent Protein Kinases; Hot Temperature; Hyperalgesia; Isoenzymes; Male; Nerve Fibers; Nociceptors; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Physical Stimulation; Protein Kinase C; Protein Kinase C-epsilon; Rats; Rats, Sprague-Dawley | 2001 |
The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Drug Interactions; Female; Growth Inhibitors; Infusions, Parenteral; Injections, Subcutaneous; Interleukin-6; Leukemia Inhibitory Factor; Lymphokines; Mammary Neoplasms, Experimental; Paclitaxel; Peripheral Nervous System Diseases; Rats | 2001 |
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Topics: Acute Disease; Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Bone Marrow; Drug Administration Schedule; Drug Evaluation; Female; Fluorescent Antibody Technique; Humans; Leukemia; Male; Microtubules; Middle Aged; Mouth Mucosa; Paclitaxel; Peripheral Nervous System Diseases; Stomatitis | 1989 |
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Cisplatin; Drug Evaluation; Epilepsy, Tonic-Clonic; Female; Hematologic Diseases; Humans; Joint Diseases; Muscular Diseases; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases | 1989 |
Taxol-induced neuropathy: further ultrastructural studies of nerve fibre changes in situ.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Axons; Male; Microtubules; Myelin Sheath; Nerve Fibers; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Inbred Strains; Schwann Cells | 1985 |